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INTRODUCTION
Research in the field of pharmaceutical has its most important task in the
development of new better drugs and their successful introduction into clinical practice.
Central to these efforts, accordingly stand the search for pharmaceuticals substances
and preparation which are new and original. In addition to these objectives, we may
search for newer drugs which exhibit some clear advantages over a drug already known.
Such advantages may be qualitative or quantitative improvement in activity, the absence
of undesirable side effect, lower toxicity, improved stability or decreased cost.
The word 'drug' is derived from the French word 'drogue' which means a dry
herb. According to "WHO" a drug may be defined as "any substance or product which
is used or intended to be used for modifying or exploring physiological system or
pathological status for the benefit of recipient".
Pure organic compounds, natural or synthetic, together with so-called
organometallics are the chief source of agents. For the cure, the mitigation or the
prevention of disease today. These remedial agents have had their origin in a number of
ways; first from naturally occuring materials of both plant and animal origin and second
from the synthesis of organic compounds whose structures are closely related to those of
naturally occuring compounds (eg. morphin, atropine, steroids and cocaine) that have
been shown to possess useful medicinal properties.
There are two main divisions of medicinal chemistry. The first chemotherapy,
concerns the treatment of infections, parasite or malignant disease by chemical agents,
usually substances that show selective toxicity towards the pathogen. The other division
relates to diseases of bodily disfunction and the agents employed are mainly compounds
that effect the functioning of enzymes, the transmission of impulses or the action of
13
hormones on receptors. Heterocyclic compounds are used for all these purposes; because
they have a specific chemical reactivity. The introduction of heterocyclic groups into
drugs may effect their physical properties, for example the dissociation constants of sulpha
drugs or modify their patterns of absorption, metabolism or toxicity.
During the period of 1930-1950 there was an urgent need for new drugs to treat
diseases which had a high mortality rate, there was only limited appreciation of the
hazard such drugs might present, and toxicological studies before clinical trials were
fairly rudimentary. Proving the proverb "Necessity is the mother of invention",
during the decade of 30 & 40s a large number of important drugs introduced. Therefore
this period is regarded as "Golden Period" of new drug discovery.
Some specific examples representing new therapeutics are summarised here. In
1893 the first antibacterial drug prontosil leading to various sulpha drugs; 1940 - penicillin,
antibiotic; 1945 - chloroquine, antimalarial; 1950 - methyldopa, antidiabetic;
1958 - coronary vasodilators; 1960 - semi synthetic penicillins, antibacterial;
1965 - trimethoprim, antimicrobial; 1967 - disodium chromoglycolate,
antiallergic; 1972 - antagonist; 1981 - captopril, antihypertensive.
AIMS AND OBJECTIVES
The placement of a wide variety of substituents on these nucleii have been
designed in order to evaluate the synthesised products for their better pharmacological
profile against several strains of bacteria, fungi and some clinical isolates.
Taking in view of the applicability of heterocyclic compounds, we have undertaken
the preparation of heterocycles bearing triazole nucleus.
1. To generate several triazoles, thiadiazoles, thiadiazepines, thiadiazines, schiff bases
and sulphonamide bearing trazole moiety.
2. To generate several thiadiazoles using microwave irradiation.
14
3. To check the purity of all compounds using thin layer chromatography.
4. To characterise these products for structural elucidation using various
spectroscopic techniques like IR, PMR and Mass spectral study.
5. To evaluate these new products for better drug potential against different strains of
bacteria and fungi.
6. All the compounds have been sent to "Tuberculosis Antimicrobial Acquisition and
co-ordinating Facility (TAACF), Southern Research Institute, U.S.A." for in vitro
antitubercular activity.
In a programmed research directed towards the construction of physiologically
active new heterocycles bearing 1,2,4-triazole nucleus has been investigated.
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[A]
STUDIES ON
1,2,4-TRIAZOLES
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INTRODUCTION
Five membered ring with three nitrogen atoms is known as triazole. They
are of two types 1,2,3-triazole (I) and 1,2,4 triazole (II).
The earlier publications1,2 deal briefly with the chemistry of 1,2,4 triazoles.
Bladin synthesised the first derivatives of 1,2,4-triazole in 1885. 1,2,4-Triazoles
are not only known for their medicinal application, but also used as analytical
reagents3, dyes and photographic chemicals4 and in the preparation of
polymers5.
SYNTHETIC ASPECT
Prac t i ca l ly,  a l l  syn thes i s ing  methods  o f  t r iazo les  s ta r t s  w i th
thiosemicarbazide or, dithiocarbamate derivatives possessing nitrogen containing
functions, that is the starting material. Different methods for the preparation of
triazole derivatives are as under.
1. By the reaction of Acid hydrazide with
(a) Carbon disulphide, Al. KOH under cyclisation with amine, hydrazine
(b) Isothiocyanate followed by Ring closure with sodium hydroxide.
2. Reaction of aryl acid hydrazide with CS2/KOH and Hydrazine hydrate
furnished triazoles it is reported by Reid and Heindel6.
CHHC
N N
N
H
CHN
HN N
C
H
12
3
(II)(I)
4
5
12
4
53
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3. Treatment of Ferrocenecarboxylic acid hydrazide with aryl isothiocyanate
produced substituted thiosemicarbazides gave 3,4 disubstituted-4H-1,2,4-
triazole-5-thiol by Yan Shiquaing7.
4. B. Shivarama Holla and coworkers8have synthesised bis-3-mercapto-4-
amino-1,2,4-triazoles.
5. Reaction of thiosemicarbazide with Formic acid in presence of Acetic
anhydride (AC2O) by Shin-ichi Nagai
9.
R – C – NH.NH2
O
CS2
KOH
N2H4
N
N N
SHR
NH2
R – C – NH – NH – C – S K
O S
– +
( III )
N
N N
SMe
Ph
F3C
( IV )
N
N
NH
S N – NH2
N
N
N
R N
N
S
HCOOH
AC2O
(VI )R
2
R
1
R
1
R
2
R
H2N-HN-CS-NH-NH 2 O
N
NH2
SH
N
N
O N
N
N
SH
NH2
O-CH 2-COOH
O-CH 2-COOH
( V )
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6. Vershilov and coworker10 synthesied 3-perfluoro substituted 1,2,4-triazolyl-
5-amines and 5-thiols by reaction of  R-CO-F with NH2-NH-CX-NH2
(X=NH, S) to give R.CO.NH.NH.CX.NH2 followed by intramolecular
cyclization.
7. Kee-Jung Lee et al.11 have been prepared 1,2,4-triazole from the
electrocyclic reaction of conjugated heterocumulenes.
8. Marugan V. et al.12 have been prepared 1,2,4-triazole from cyclisation
thiosemicarbazide and the compounds are also checked for antifungal and
antibacterial activity.
9. Chande et al.13 prepared 4-anilino-5-mercapto-S-triazoles from b-acyl
dithiocarbazinate and phenyl hydrazine at 140-160oC.
N
N NH
YR
( VII )
R = C6F13, C3F7O.C3F6O.CF(CF)3
Y = NH2, SH
N
H3C NH
O
N
H
Ph
N
RPh
Ph3P,CCl4,Et3N
CH2
.Cl2 N
H3C
N
RPh
N
. Ph
N
N – PhN
N
N
Me
PhPh
( VIII )
R – C – NH – NH – C – S – K
O S
+
140-160oC
C6H5
.NH.NH2
N
N
R SH
N
NH
H5C6( X )
–
( IX )
N
N
H
S
CO NH NH
S
NH
Ph
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10. Nicolo Vivona & coworkers14 synthesized 1,2,4-triazole and its derivatives
from 1,2,4-oxadiazole.
BIOLOGICAL IMPORTANTS
( XI )
N
N
N
NN
1. Amitrole 2. Letrozole
N N
NH
3. Bitertanol 4. Brotizolam
Antineoplastic
Antithyroid activity
O
OH
N
N
N H3C
CH3H3C
N
N
N
CH3
N
S
Br
Cl
Agriculture fungicide Sedative Hypnotic
5. Diclobutrazole 6. Diniconazole
Cl
Cl
OH
CH3
CH3
H3C
NN
N
Cl
Cl
NN
N
CH3
CH3
H3C
OH
Agriculture fungicideRegulation of Plantgrowth
NH2
N
N O
Ph R N
N N
Ph R
CH3
Me NH-NH2
DMF
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ClN
NNN
N
O
H3C
F
OH
N
N
N
N
N
N
F
9. Paclobutrazole
Cl
NN
N
CH3
CH3
H3C
OH
Plantgrowth regulator
10. Propiconazole
Cl
Cl
NN
N
O
O
H3C
Antifungal
11. Rilmazafone
Cl
O
Cl
N
N
N O
N – CH3
H3C
Sedative, Hypnotic
12. Triazophose
N
N
N
O
P
O
S O CH3
CH3
7. Nefazodone
Antidepressant
8. Fluconazole
Antifungal
O
Pesticide
O
OHHO
HO
N
N
N
C
H2N
O
Antiviral,
Antiinfectious
13. Ribavirin
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BIOLOGICAL EVALUATION
1,2,4-Triazoles display significant biological activities. 3-Amino, 1,2,4-
triazole (Amitrote, Amizol, AJA, Weedazole) was the first 1,2,4 triazole to be
manufactured on a large scale from aminoguanidine formate15 for use as neutral
herbicides. It has been used successfully in the control of fungal infection16 and
nematicidal activity17. Various triazole derivatives have been shown to inhibit
eosinophilia18, to have hypoglycemic activity19 and also possess microbicides20
for plant protection and materials preservation.
Emilsson Haakan21 have prepared several triazole as anti hypertensive
activity and have been reported 4-amino-3-Hydrazino-5-isopropyl-4H-1,2,4-
triazole was the most potent one with a 20% reduction in blood pressure at 40
mmol/kg. The pharmacological fate of the antidepressant profile and antimicrobial
potency22 (XII) of indoyl-1,2,4-triazole have been documented by Varvaresou
Athanasia and co-workers. Tsukuda Takuo et al.23 have been synthesised
cyclohexyl analogs of 1,2,4 triazole, in vitro and in vivo antifungal activity were
determined (XIII).
Baba Atsuo et al.24 suggested that triazole derivative are useful in
antirheumatic drugs. Various 3-substituted-4-amino-5-mercapto-4(H)-1,2,4-
triazoles as nonsteroidal antiinflammatory, ulcerogenic liability, antimicrobial and
antituberculosis agents have been reported by Laddi U. V. and coworkers25. Amir
Mohammad have prepared 1,2,4 triazole derivative as anti inflammatory activity26
(XIV). In vitro antimicrobial activity of 2,4-dihydro-4-benzyl-5 (isomeric pyridyl)-
3H-,1,2,4-triazole-3-thiones have been documented by Iqbal Rashid & Rama
Nasim27. Shi, Yan-Nian and co-workers28 have prepared 2H, pyrazolo, 1,2,4-
triazole as plant growth regulator activity (XV).
N
H
Me
CH2
N
N
NH
S
R
R.CH2
.H2C
MeO
CH2
CH2OR
'
( XIII )
N
NN( XII )
Me
21
Bignon Eric et al.29 have been reported N-triazolyl-2-indole carboxamides
and their use as CCK-A agonists. These compounds have partial or total CCK-A
receptor agonist activity and are useful for treating eating problems, obesity, tardive
dyskinesia and disorders of the gastrointestinal sphere (XVI). Some novel 1H,
1,2,4 triazole derivatives possessing antiviral (anti influenza virus), antibacterial
and antifungal agents by Spyroula et al.30 (XVII).
Jag Mohan et al.31 have synthesised 5-Substituted-2-(a-naphthyl) thiazolo
[3,2-b]-s-triazoles (XVIII). The compounds were studied for their antimicrobial
activity against Gram positive (Staphylococcus aureus) and Gram negative
(Escherichia coli and Pseudomonas aeruglonosa) bacteria and the fungus
Candida albicans by neat sample and seria dilution method. Various 1,2,4 triazole
derivatives possess potential antitumor agents32. (XIX).
N N
R
S
N
N
N
R'
H2CCH
Me
Me2CH.H2C
SH
( XIV )
N
N – Ph
N
N
N
R2
R1
( XV )
NH – C N
R'
(XVI)
O
N
N
NR'
R
N
N
N
R
R'
N
N
( XVII )
(XVIII)
F
N
N
N
SHH2C
S
N
H2N
(XIX)
N
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Rollas Sevim et al.33 have been synthesized 5-(4-fluorophenyl)-4-
Substituted-2,4-dihydro-3H-1,2,4-triazole-3-thione derivatives as antimicrobial
and anticonvulsant agents (XX). Several triazole indicates potent cardiovascular34
effects. Pittam John and Taylor Nigel35 have prepared azole as antifungal agent
(XXI). The azole (XXI) is effective at 1-200 mg per day against human fungal
infection.
Dickinson Roger P and co-workers have prepared voriconazole36
antifungal high activity against Aspergillus fumigatus (XXII) and a -
(heteroarylmethyl)-1H-1,2,4-triazole 1-ethanol derivatives are active against
Candida albicans and Cryptococous neofermans37 (XXIII).
A number of 1H-1,2,4-triazole38-41 derivatives have been reported to
show broad spectrum biological activities, some of which were commercialized
as agrochemical fungicides, Insecticides, herbicides and platn growth regulator
N
N
NH
R
F S
(XX)
NN
N
NN
N
O
CF2
CF2HF
F
OH
(XXI)
F
OH Me F
N N
NN
N
F
F
OH Me
NN
N
F
N
O
(XXII) (XXIII)
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CH2
Cl
activities. Sikorski James A.42 have been documented 1,2,4-triazole are useful
for inhibiting cholesteryl ester transfer protein activity. Anticonvulsants43 activity
of several triazoles have reported by Cesur Nesrin and Cesur Zafer. Jautelat
Manfred44 and co-workers have been reported 1,2,4 triazole derivative as 100%
inhibition of Erisyphe graminis on barley (XXIV).
Heindelned et al.45 have synthesised 1,2,4-triazoles as nitric oxide
synthatase inhibitor and following triazoles(XXV) are also claimed for oral, topical,
nasal and rectal administration.
The therapeutic activities shown by 1,2,4-triazole derivatives are listed as
follows :
1. Oxytocin antagonists46
2. Diuretic47
3. Antiarthritic48
C Cl
OH
CH2
N
N
N
S
N
NS
OH
Cl
N
C
CH2
Cl
(XXIV)
CH2
N
N N
SHR
N R1
N
N N
SR
N
R2
Ar
X
R = alkyl, aryl H, halo,2-thienyl,heterocyclyl
R1 = -CH=CH-Ph, alkyl, aryl, halo, H
R2 = Methyl X = Cl, Br
(XXV)
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4. Antiviral49
5. Anthelmintics50
6. Antihypertensive51
7. Antipsychotic52
8. Bactericidal53
9. Insecticidal & Acaricides54
10. Fungicidal55
11. Anticonvulsant56
12. Anticancer and anti HIV57
13. Antimicrobial58
14. Plant Growth Regulator59
15. Antithrombotic60
16. Herbicidal61
17. Antileishmanial62
Antigestative immunosuppressant and antitumor63 activity of substituted
1,2,4-triazole have been reported. Michael et al.64 have prepared triazole as
potential antibacterial activity against Gram Negative organism Haemophilus
influenzae and Moraxella catarrhalis. Antimicobacterial activity of substituted
triazole have been documented by Mikail H. and co-workers65. Diverse
pharmacological activities66 and antifungal67 activity of w-(1-aryl-5-methyl-
1,2,3-triazole-4-carboxyl)-w-(1H-1,2,4-triazol-1-yl) acetephenone have been
reported.
25
Thus the important role displayed by triazole moiety for various therapeutic
and pharmaceutical activities prompted us to synthesise some thiadiazines,
thiadiazepins, azomethines, sulphonamides and aryl triazoles derivatives bearing
triazole moiety, in order to achieve compounds having better drug potential. This
study is described in the following parts.
PART - I : STUDIES ON AZOMETHINES
PART - II : STUDIES ON 1,3,4-THIADIAZINES
PART - III : STUDIES ON 1,3,4-THIADIAZEPINES
PART - IV : STUDIES ON SULPHONAMIDES
PART - V : STUDIES ON 4-ARYLTRIAZOLE DERIVATIVES
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PART - I
STUDIES ON
AZOMETHINES
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INTRODUCTION
Azomethines are imino compounds which are formed by the reactions
of a primary amine with aldehydes or ketones. The reaction scheme can be given
as following.
When one or both of the reactants is aromatic, the imine is quite stable
and usually known as a Schiff base or aldimine. In the case of wholly aliphatic
reactants the imines tend to decompose or polymerise, in these cases their further
reaction is carried out without delay. Enamines are the stable products of a similar
reaction between secondary amines and aldehydes and ketones68. The reaction
between amine and formaldehyde followed by further reaction with compounds
having active hydrogen gives mannich bases.
SYNTHETIC ASPECT
Azomethines can be formed by the reaction of a primary amine with
aldehyde with the simultaneous removal of water for example by azeotropic
distillation69 by the addition of anhydrous sodium sulphate70, by the addition
of moleculer sieves71 or by the use of titanium (IV) chloride72. A typical
(I)
R1
C
O
H R2 - NH2
R1
C
N - R2
H
R1 , R2 = Alkyl, Aryl
27
procedure involving water removal with anhydrous potassium carbonate is given
in litrature73.
The initial N-substituted hemiaminals lose water to give the stable Schiff
bases which have been observed spectrally74.
BIOLOGICAL EVALUATION
From the literature survey it was revealed that schieff base derivatives
are better therapeutic agents as wel l  as intermediates for many useful
compounds75-81.
Holla B. S. et al.82  have documented some 3-Substituted 1-(amino
methyl)-4-[5-(4-nitrophenyl-2-furfurylidene)-amino]-1,2,4-triazole-5-thiones(III)
and tested their antibacterial activity.
(II)
R1
C
O
H
R2 - NH2
R1
C
N - R2
H
R1 , R2 = Alkyl, Aryl
+
R1
C
OH
H
NR2 -H2O
N
N
S
N = CH
(III)
N
R
CH2 – R'
O
NO2 R = Me, Et, Pr, Ph
R' = morpholino
4-methyl
piperazinyl
piperidino
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Anand K.83 and co-workers have been synthesized some Mannich derivatives
and tested their antifungal and antibacterial activity (IV).
Moreover Shingare M. S. et al.84 have described the synthesis and the
antiviral activity of some enamines(V).
Alain Nuhrich and co-workers85 have reported some fungistic  active
schiffbases(VI) as shown under.
O
N NH
O
OH
OH
X
X
CH3
R
X = H,    R = 4-F
X = Cl,   R = 4-F
(VI)
N
N
S
CH2 – NH
CH2
N
S
R
R
N
S
R = H, 4-Me, 5-OMe,
5-Cl, 6-Br
(V)
N
N
S
N = CH
N
R
CH2 – N
N
R1
R2
CH3
Cl
N
Ph
(IV)
R = CH3, C2H5, C6H5
R1, R2 = p-chloroaniline
= morpholine
= diphenyl aniline
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Keeping in view of these valid observations prompted us to synthesise Schiff
bases bearing 1,2,4-triazole moiety. So as to enhance the overall activities of
resulting moiety, which have been descruibed as under.
SECTION - I : PREPARATION AND BIOLOGICAL EVALUATION OF
4-N-SUBSTITUTED BENZALAMINO-3-MERCAPTO-5-
(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 4-N-
S U B S T I T U T E D  B E N Z A L A M I N O - 3 - M E R CA P T O - 5 -
(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
In view of getting better therapeutic agent and considering the association
of various biological activity with 1,2,4-triazole nuclei, the preparation of schiff's
bases of type (I) have been undertaken by the condensation of 3-mercapto-4-N-
amino-5-(1'-naphthylmethyl)-1,2,4-triazole with different aromatic aldehydes, as
shown in Reaction Scheme (I).
The constitution of the products have been established by using elemental
analyses, infrared spectroscopy and 1H nuclear magnetic resonance spectroscopy
and further confirmed by mass spectrometry86. In mass spectroscopy
when R=p-anisyl m/z = 375 indicates the moleculer weight of the compound.
All the newly synthesised compounds have been screened for their in vitro
biological assay like antibacterial activity towards Gram positive and Gram
negative bacterial strains and antifungal activity towards Aspergillus niger at a
concentration of 40 mg. The biological activities of the synthesised compounds
have been compared with standard drugs. The details have been cited in Part - I,
Section - I (E).
N
N
N
SH
N
R
R = Aryl
30
NH
NH2
O
N
N
N
SH
NH2
N
N
N
SH
N
R
Type ( I )            R = Aryl
OC2H5
O
NH2-NH2  H2O
EtOH, KOH
CS2
NH NH
O S
SK
_ +
NH2-NH2  H2O
R-CHO
Con.  H2SO4
REACTION SCHEME
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Type Vibration                Frequency in cm-1 Ref.
mode Observed Reported
IR SPECTRAL STUDY OF 4-N-p-METHOXYBENZALAMINO-3-MERCAPTO-5-
(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLE
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
22.0
% T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cm
Alkane C-H str. (asym.) 2921 2975-2950 351
-CH3 C-H str. (sym.) - 2880-2860 ,,
C-H  i.p. def. 1448 1470-1435 ,,
C-H o.o.p. def. 1394 1395-1370 ,,
Aromatic C-H str. 3045 3080-3030 ,,
C=C str. 1577 1585-1480 ,,
1508 1585-1480 ,,
C-H i.p. def. 1074 1125-1000 352
C-H o.o.p. def. 833 835-810 ,,
Triazole C=N str. 1629 1650-1550 353
S-H str. - 2550-2400 ,,
C-N str. 1394* 1470-1360 ,,
Ether C-O-C str. (asym.) 1238 1275-1200 352
C-O-C str. (sym.) 1074* 1075-1020 ,,
Schiff's base -C=N str. 1596 1660-1580 354
* = overlap
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Freq. range 4000-400 cm-1 (KBr disc.)
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N
N
N
SH
N
OCH3
a b
c
d
e
f
g h
i
a' b'
Internal reference : TMS
Solvent : CDCl3 + DMSO-d6
Instrument : BRUKER Spectrometer (300 MHz)
Interpretation of Spectrum :
Signal Signal Position Relative No. Multiplicity Inference
No. (d ppm) of proton
1 3.89 3H singlet Ar–OCH3
2 4.59 2H singlet –CH2–
3 6.96 2H Doublet Ar–H (bb')
4 7.35 1H Doublet Ar–H (h)
5 7.41 1H Doublet Ar–H (d)
6 7.45 1H Doublet Ar–H (c)
7 7.49 - 7.54 2H Multiplate Ar–H (i,e)
8 7.76 2H Doublet Ar–H (aa')
9 7.83 - 7.86 1H Double Doublet Ar–H (g)
10 8.10 1H Double Doublet Ar–H (f)
11 9.89 1H Singlet CH=N
12 10.03 1H Broad Band –SH
N
N
N
SH
N
OCH3
a b
c
d
e
f
g h
i
a' b'
PMR SPECTRAL STUDY OF 4-N-r-METHOXYBENZALAMINO-3-MERCAPTO-
5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLE
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N N
N SH
N O CH3
m/z = 374. 5
ANTIMICROBIAL ACTIVITY
Method : Cup-plate87
Gram positive bacteria : Staphylococcus aureus
Bacillus megaterium
Gram negative bacteria : Proteus vulgaris
Escherichia coli
Fungi : Aspergillus niger
Concentration : 40 µg
Solvent : Dimethyl formamide
Standard drugs : Ampicillin, Amoxicillin, Ciprofloxacin,
Erythromycin, Greseofulvin.
The antimicrobial activity was compared with standard drugs viz.,
Ampicillin, Amoxicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with viz. Greseofulvin. The zones of inhibition have been measured in
mm.
ANTITUBERCULAR ACTIVITY
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and Co-ordinating Facility (TAACF) U. S. A.
Method : BACTEC 460 Radiometric system
Bacteria : Mycobacterium tuberculosis H37Rv
Concentration : 6.25 µg/ml
Standard drug : Rifampin
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EXPERIMENTAL37
PREPARATION AND BIOLOGICAL EVALUATION OF 4-N-
SUBSTITUTED BENZALAMINO-3-MERCAPTO-5-
(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
(A) Preparation of 1'-Naphthyl acetohydrazide88
A solution of ethyl 1'-naphthylacetate (21.4ml, 0.1 M), absolute ethanol
(25 ml) and hydrazine (95%, 10ml, 0.2 M) was refluxed for 6 hrs. The content
were cooled and poured onto crushed ice and filtered, washed with hot water
and dried. Yield 19.2g, 96%, m.p. 170oC89.
(B) Preparation of Potassium 1'-naphthyl acetamido dithiocarbamate
A solution of potassium hydroxide (8.40g, 0.15 M), absolute ethanol (50
ml) and 1'-naphthyl acetohydrazide (20.0g, 0.1 M) was treated to the addition of
carbon disulfide (11.4g, 0.15 M). This mixture was diluted with absolute ethanol
(25 ml) and agitated for 15 hours. It was then diluted with 200 ml of dry ether
and the precipitated solid was filtered, washed with ether and dried. Yield 29.8g,
95%.
(C) Preparation of 3-Mercapto-4-N-amino-5-(1'-naphthylmethyl)-
1,2,4-triazole
A suspension of the Potassium 1'-naphthyl acetamido dithiocarbamate
(7.85g, 0.025M), hydrazine (95%, 5ml, 0.1 M) and water (2 ml) was refluxed
with stirring for 2 hours. A homogenous solution resulted with change in colour
to green. It was diluted with water and acidify with gl. acetic acid gave white
precipitate. This product was filtered washed with cold water and crystallised
in DMF. Yield 3.97g, 62%, m.p. 255oC.
(D) Preparation of 4-N-ρ-Methoxybenzalamino-3-mercapto-5-
(1'-naphthylmethyl)-1,2,4-triazole
ρ−Anisaldehyde (1.36g, 0.01 M) in methanol (20ml) was added to 3-
mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-triazole  (2.56 g, 0.01 M), and
refluxed for 6 hrs after addition of  conc. H2SO4 (0.2ml). The content were poured
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in crushed ice and the product was isolated and crystallised form  methanol. Yield
2.8g, 48%, m.p. 156oC. ( C21H18N4OS, Required: C, 67.36; H, 4.85; N, 14.96;
Found : C, 67.44; H, 4.75; N, 14.84%, TLC Acetone : Benzene (4 : 6), Rf : 0.67).
Similarly, other aromatic aldehydes were condensed. The physical constant
are recorded in Table No. 1.
(E) Biological  evaluat ion of  4-N-Subst i tuted benzalamino-
3-mercapto-5-(1'-naphthylmethyl)-1,2,4-triazoles
All the products have been evaluated for antimicrobial activity as described
under.
(a) Antimicrobial activity
It was carried out by cup-plate diffusion method which is described as under.
(I) Antibacterial activity
The purified products were screened for their antibacterial activity. The
nutrient agar broth prepared by the usual method, was inoculated aspetically
with 0.5 ml of 24 hrs. old subcultures of B. megaterium, S. aureus, E. coli, P.
vulgaris in separate conical flasks at 40-50oC and mixed well by gently shaking.
About 25 ml content of the flask were poured and evenly spreaded in a petridish
(13 cm in diameter) and allowed to set for 2 hrs. The cups (10 mm in diameter)
were formed by the help of borer in agar medium and filled with 0.04 ml (40 mg)
solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also
maintained with 0.04 mol of DMF in a similar manner and the zones of inhibition
of the bacterial growth were measured in millimeter and are recorded in graphical
chart no. 1.
(II) Antifungal activity :
A. niger was employed for testing antifungal activity using cup-plate
method. The culture was maintained on Sabouraud's agar slants. Sterilised
Sabouraud's agar medium was inoculated with 72 hrs. Old 0.5 ml suspension of
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fungal spores in a separate flask was taken. About 25 ml of the inoculated medium
was evenly spreaded in a petridish and allowed to set for two hrs. The cups (10
mm in diameter) were punched. The plates were incubated at 30oC for 48 hrs.
After the completion of incubation period, the zones of inhibition of growth in
the form of diameter in mm was measured. Along the test solution in each petridish
one cup was filled with solvent which act as control. The zones of inhibition are
recorded in graphical chart no. 1a.
EXPERIMENTAL
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1a 2-Cl-C6H4- C20H15N4SCl 378.8 174 35 0.61 14.79 14.76
1b 3-Cl-C6H4- C20H15N4SCl 378.8 190 52 0.46 14.79 14.81
1c 4-Cl-C6H4- C20H15N4SCl 378.8 180 47 0.50 14.79 14.80
1d 2:4-(Cl)2-C6H3- C20H14N4SCl2 413.3 158 43 0.56 13.56 13.60
1e 3:4 (OCH3)2-C6H3- C22H20N4O2S 404.4 182 45 0.49 13.85 13.82
1f 2-OH-C6H4- C20H16N4OS 360.4 130 66 0.68 15.54 15.51
1g 4-OH-C6H4- C20H16N4OS 360.4 144 61 0.64 15.54 15.53
1h 4-OCH3,3-OH-C6H3- C21H18N4O2S 390.4 164 45 0.69 14.35 14.38
1i 4-OCH3-C6H4- C21H18N4OS 374.4 156 48 0.67 14.96 14.92
1j C6H5-CH=CH- C22H18N4S 370.4 172 59 0.64 15.12 15.15
1k 2-NO2-C6H4- C20H15N5O2S 389.4 198 57 0.53 17.98 17.97
1l 3-NO2-C6H4- C20H15N5O2S 389.4 165 55 0.60 17.98 17.95
* TLC Solvent System : Acetone : Benzene : (4 : 6)
Comp.
No.
1
TABLE NO. 1 :  PHYSICAL CONSTANTS OF 4-N-SUBSTITUTEDBENZALAMINO-3-MERCAPTO-5-
(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
Found
9
M.P.
oC
5
Calcd.
8
% of NitrogenMolecular
Formula
3
R
2
Molecular
Weight
4
Yield
%
6
Rf*
Value
7
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GRAPHICAL CHART NO. 1 :  4-N-SUBSTITUTED-BENZALAMINO-3-MERCAPTO-5-(1'-NAPHTHYLMETHYL)-
1,2,4-TRIAZOLES

















































































































0
5
10
15
20
25
30
zo
ne
 o
f 
in
hi
b
it
io
n 
in
 m
m
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s.aureus 13 12 16 18 10 15 19 14 18 12 13 16 22 23 1
E.coli 18 15 14 13 15 17 16 15 12 16 15 18 21 21 2

 P.vulgaris 11 13 12 8 17 13 15 11 13 14 10 13 15 18 1
A .niger 18 15 17 15 13 17 18 19 20 16 17 15 0 0 0
1a 1b 1c 1d 1e 1f 1g 1h 1i 1j 1k 1l A m pi
cillin
A m o
xycill
in
N o
ox
n
4
2
1d (20) 1d (18) 1a (18) 1e (17) 1i (20)
1k (21) 1g (19) 1l (18) 1g (15)
1i (18)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART - I
Section - I :Antimicrobial activity of 4-N-Substitutedbenzalamino-3-mercapto-5-(1'-naphthylmethyl)-1,2,4-
triazoles
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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PART - II
STUDIES ON 1,3,4-
THIADIAZINES
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INTRODUCTION
In six member ring system, the presence of two nitrogen and one sulfur
hetero atoms defines an interesting class of compounds, the thiadiazines. These
may be of four types (I), 2H-1,2,4-Thiadiazine; (II), 2H-1,2,6-Thiadiazine; (III),
2H-1,3,4-Thiadiazine and (IV), 2H-1,3,5-Thiadiazine.
1,3,4-Thiadiazine derivatives are studied extensively because it represents
one of the most active class of compounds possessing a wide spectrum of
pharmacological activities90-92. Many 1,3,4-thiadiazine derivatives involve in
many biological processes and serves as an synthetic drugs. Including various
medicinally interesting compounds, 1,2,4-thiadiazines are useful for the synthesis
of tri and tetracycle heterocyclic compounds.
SYNTHETIC ASPECT
Different methods for the preparation of 1,3,4-thiadiazine derivatives
documented in literature are as follows.
1. Campaigne E. and Selby T. P.93 have prepared 1,3,4-thiadiazine by the
condensation of ethyl-4-chloroacetoacetate with thiosemicarbazide.
2. The 1,3,4-thiadiazine can also be prepared by the action of cyclic α-
haloketones with 3-mercapto-4-amino-5-ethyl-1,2,4-triazole gave 1,3,4-
thiadiazines94.
S
NH
N
1
2
3
4
5
6
S
NHN
S
N
N
S
NN
(I) (II) (III) (IV)
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O
Br(CH2)n
+
N
N
N
H2N
HS
Et
(CH2)n S
N
N
N
N
Et
(V)
3. Neanhoeffer Hans et al.95 have been synthesized 1,3,4-thiadiazine from
the cyclization of the [(thioacyl) hydrazino] triazines in mineral acid to afford
1H-[1,2,4] triazino [5,6-e] [1,3,4] thiadiazines.
4. Reaction between amino mercapto triazole with 2,3-dichloro quinoxaline
in presence of sodium acetate to form 1,3,4-thiadiazine which have  been
documented by Jag Mohan96.
5. Prasad Altaluri R. et al.97 have synthesized 3-aryloxy-alkyl-6-aryl-7H-s-
triazolo [3,4-b] [1,3,4] thiadiazines. 1,2,4-Triazole react with phenacyl
bromide gave 1,3,4-thiadiazine.
N
N
N C6H4.Me.p
S
N
H
H2N
C
O
H3C
mineral acid
N
N
N C6H4
.Me.p
S
N
H
N
Me
(VI)
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NSH
NH2
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N
NH2
SH
N
N
Cl
Cl
+
N
N S
H
N
N
N
N
S
H
N N
N
N
N
N
(VII)
O.C
N N
N
NH2
SH
R2R3
R4
R2R3
(VIII)
R4 O.C
N N
N S
R
R.COCH2
.Br+
R = Ph, 4-Br-C6H4
R' = H, Me, R2,R3,R4 = H, Cl
N
2
H
R'
H
R'
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6. Ibrahim Yehia A. and co-workers98 have been documented. Stereo specific
synthesis of 6,7-dihydro-5H-1,2,4-triazolo [3,4-b] [1,3,4] thiadiazines.
7. Cyclization of 4-amino-3-mercapto-6-methyl [1,2,4] triazine-5-one with
phenalycl bromide have reported by Heravi M. M. et al.98.
8. Jia Guofeng and Li Zhengming100 have synthesized new substituted
4-arylsulfonyl-4H-1,3,4-thiadiazin-5 (6H)-ones by the cyclization of
R'.C6H4.So2.NH.NH (CS)-NH-C6H4.R
2 with chloroacetyl chloride,
provided the corresponding thiadiazines.
9. Santagati Maria101 and Debellis Francesco102 have recently described that
the condensation of hydrazines with R'.CO2H in organic solvents in the
presence of POCl3, PSCl3, POBr3, PSBr3, PCl3, PBr3, PI3, PCl5 or P4O10.
N N
N SHR
N
CH–Ar
+ R'CO.CH2
.Br
Et3N
NaBH4
DMF N N
NR
HN
S
H
Ar
H
R'
(IX)
R = Ph, 4-Me-O-C6H4
Ar = Ph, R' = CO2Et, CO
.Ph
N
N
O
Me
S N
Ph
N
MeN
N
N
HS O
NH2
+ Ph.CO.CH2
.Br
(X)
SO2–N
N
S
O
NH
R2
NH – C
SR'–C6H4–SO2–NH
(XI)
NH
Cl.CH2CO
.Cl
R2 R'
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10. M. Rahimizadeh et al.103 can be prepared 1,3,4-thiadiazine by the
cyclization of 2,4-dichloro-6-methyl-5-nitro pyrimidine with dithizone.
11. Nicolo Vivona et al.104 have been reported some thiadiazines(XIV) which
is supposed to be highly potent in herbicidal.
BIOLOGICAL IMPORTANCE
Literature survey reveals that various 1,3,4-thiadiazine have resulted in
many potential drugs and are known to exhibit a broad spectrum of biological
activities.
1,3,4-Thiadiazine derivatives possess wide therapeutic activity viz
card iovascu la r105 ,106,  an t i in f l ammatory107,  an t ibac te r ia l108  and
antifungal109 activities.
N N
S
R NH.NH2 + R
'.COOH
R N
S N
N
R'
(XII) R = H, substituted group
R' = substituted group
N
(XIII)
(XIV)
N
N
NO2
Cl Cl
Me
+ Ph–NH–NH–C–N=N–Ph
S
N
N
Cl
Me
N
S
N
R
PhR = N = N – Ph
– NH2
– NH – CH2 – CO – Ph
N
N
S
N
R1
NH2
R2
N
S
N
R1
NH2
R2
R1 = C4-C8 alkyl, Cycloalkyl
R2 = aryl, alkyl, fluoroalkyl, heteroaryl
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Mohan Jag and Singh Virender110 have synthesized s-triazolo [3',4' : 2,3]
[1,3,4] thiadiazino [5,6-b] quinoxalines  and s-triazolo [3,4-b] [1,3,4] thiadiazines
and tested for their antimicrobial activity. Jonas Rochus et al. have prepared new
thiadiazine derivative useful as phosphodiesterase IV inhibitors111 and
cardiovascular agents112. Kalluraya B. et al.113 have reported 3-substituted-6-
(6-bromo-3-coumarinyl)-s-triazolo [3,4-b] [1,3,4] thiadiazine and subjected to
antibacterial activity. Lee, An Rong Taiwan114 have been patented triazolo
thiadiazine as antiinflammatory activity.
Ergenc Nedime and co-workers115 descr ibed the synthesis  and
antimicrobial properties of new 6-aryl-3-(2-furanyl)-7H, 1,2,4-triazolo [3,4-b]
[1,3,4] thiadiazines. Also Balkrishna et al.116 synthesized thiophene heterocycles
of 6-(5-aryl-2-thienyl)-7H-s-triazolo [3,4-b]-1,3,4-thiadiazines and reported that
the chlorine containing compounds were significantly active against E. coli. Arranz
Esther et al.117 have synthesized thiadiazine derivatives as non-nucleoside
reverse transcriptor inhibitors that inhibit human Immunodeficiency virus type -
I- replications. Ho Sik Kim et al.118 have prepared 2-Arylamino 1,3,4-thiadiazino
[5,6-b] quinoxalines and mesoionic triazole [4,3-a] quinoxaline which were
assessed for arterosclerosis and thrombosis activity (XV). Antimicrobial activity
of thiadiazine containing with aryl sydnones119,120 and quinoxaline121 nucleus
have been reported.
Turan-Zitouni  G. et al.122 have prepared triazolo thiadiazines as analgesic
activity . Nizamuddin123 and co-workers synthesized thiadiazine derivatives and
N
N N
S
N
Cl
Me
N
Me
C – R
O
R = Me
(XV)
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tested their activity against Aspergillus flavus, Cephalosphorium sacchari,
Pyricylaria solani and Phytophthora inlestant at 500 ppm and 100 ppm
concentration respectively. Renuka Devi Patil and J. S. Biradar124 have reported
tr iazolo-thiadiaz ine der ivat ives as anthelmint ic ,  ant i inf lammatory and
anticatatonic activity (XVI).
Fur thermore Kamal Ahmed and co-workers125 have done recent
development in the desain, synthesis and structure - activity relationship studies
on benzodiazepines as DNA-interactive antitumor antibiotics. Jag Mohan and
Anupama have reported thiadiazine as antimicrobial activity126. Antibacterial
and antifungal127 activity of some new biologically active triazino thiadiazinones
have reported. L. D. S. yadav and co-workers128 have documented a convenient
synthesis of antiviral acyclic C-nucleosides incorporating 1,3,4 thiadiazine nucleus
as nucleobase. Also A. M. Dhiman & K. N. Wadodkar129 represent some
bridgehead nitrogen heterocycles and tested their antimicrobial activity against
Salmonel la  typhi ,  Shigel la  dysenter iae,  Proteus mira ib i l i s ,  Klebs ie l la
pneumoniae and reported all compounds were highly active towards urinary tract
pathogen P. mirabilis.
The diverse biological activities have been encountered in compounds
containing triazolo-thiadiazine ring system. Therefore it was considered
worthwhile to synthesise 1,3,4-thiadiazine derivatives which have been described
as under.
N
H
Ph
N N
N
N
S
Ph
(XVI)
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SECTION - I : PREPARATION AND BIOLOGICAL EVALUATION
OF 3-MERCAPTO-4-N-AROYLAMINO-5-
(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
SECTION - II : PREPARATION AND BIOLOGICAL EVALUATION OF
5 - ( 1 ' - N A P H T H Y L M E T H Y L ) - 1 , 2 , 4 -T R I A Z O LO
[ 3 , 4 - b ] B E N Z P Y R A Z I N O [ 2 , 3 - e ] - 4 - N - A R O Y L -
1,3,4-THIADIAZINES
SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-
4-N-AROYLAMINO-5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
In view of getting better therapeutic agent and considering the association
of various biological activity with triazole nuclei, the preparation of aryl amide of
type (II) have been undertaken by the condensation of  3-mercapto-4-N-amino-
5-(1'-naphthylmethyl)-1,2,4-triazole with different substituted aroyl chlorides in
dry pyridine.
The constitution of the products has been established by using elemental
analyses, infrared spectroscopy and 1H nuclear magnetic resonance spectroscopy
and further confirmed by mass spectrometry86. In mass spectroscopy
when R=p-tolyl m/z = 373 indicates the moleculer weight of the compound.
All the newly synthesised compounds have been screened for their in vitro
biological assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H37Rv at a concentration of 6.25 µg/ml using Rifampin as
standard drug, antibacterial activity towards Gram positive and Gram negative
bacterial strains and antifungal activity towards Aspergillus niger at a
concentration of 40 mg. The biological activities of the synthesised compounds
have been compared with standard drugs. The details have been cited in Part - I,
Section - I (E).
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N
SH
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SH
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Type ( II )            R = Aryl
R-CO-Cl
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Type Vibration                Frequency in cm-1 Ref.
mode Observed Reported
35.0
40.0
45.0
50.0
55.0
60.0
65.0
70.0
75.0
80.0
85.0
90.0
95.0
100.0
105.0
% T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cm
Alkane C-H str. (asym.) 2950 2975-2950 351
-CH3 C-H str. (sym.) 2860 2880-2860 ,,
C-H  i.p. def. 1421 1470-1435 ,,
C-H o.o.p. def. 1394 1395-1370 ,,
Aromatic C-H str. 3045 3080-3030 ,,
C=C str. 1566 1585-1480 ,,
C-H i.p. def. 1074 1125-1000 352
C-H o.o.p. def. 813 835-810 ,,
Triazole C=N str. 1625 1650-1580 353
N-N str. 1024* 1050-1010 ,,
C-N str. 1147 1220-1020 ,,
C-S str. 702 700-600 ,,
Amide N-H str. 3315 3300-3100 354
-NH-CO- N-H def. 1596 1650-1580 ,,
C=O str. (amide) 1625* 1690-1630 ,,
* = overlap
N
N
N
SH
NH O
CH3
IR SPECTRAL STUDY OF 3-MERCAPTO-4-N-(ρ-METHYLBENZOYLAMINO)-
5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Freq. range 4000-400 cm-1 (KBr disc.)
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53
N N
N SH
NH O
OCH3
a
b
c
d
e
f g
h
i
a'
b'
Internal reference : TMS
Solvent : CDCl3 + DMSO-d6
Instrument : BRUKER Spectrometer (300 MHz)
Interpretation of Spectrum :
Signal Signal Position Relative No. Multiplicity Inference
No. (d ppm) of proton
1 3.88 3H singlet Ar–OCH3
2 4.91 2H singlet –CH2–
3 6.98 2H Doublet Ar–H (bb')
4 7.41 - 7.51 2H Multiplate Ar–H (d,h)
5 7.54 - 7.60 2H Multiplate Ar–H (e,c)
6 7.71 2H Doublet Ar–H (aa')
7 7.78 1H Doublet Ar–H (i)
8 7.85 1H Doublet Ar–H (g)
9 8.28 1H Doublet Ar–H (f)
N N
N SH
NH O
OCH3
a
b
c
d
e
f g
h
i
a'
b'
PMR SPECTRAL STUDY OF 3-MERCAPTO-4-N-(ρ-METHOXYBENZOYL
AMINO)-5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLE
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m/z = 374 (m-1)
N N
N SH
NH
O
CH3
PREPARATION AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-
4-N-AROYLAMINO-5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
(A) Preparation of 1'-Naphthyl acetohydrazide
See Part - I, Section - I(A).
(B) Preparation of Potassium 1'-naphthyl acetamido dithiocarbamate
See Part - I, Section - I (B).
(C) Preparation of 3-Mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-
triazole
See Part - I, Section - I (C).
(D) Preparation of  3-Mercapto-4-N-(ρ-methylbenzoylamino)-5-
(1'-naphthylmethyl)-1,2,4-triazole
A mixture of ρ-toluic acid (1.36g, 0.01 M) and thionyl chloride (5 ml) was
refluxed for 6 hrs. Excess of thionyl chloride was removed by distillation. The  acid
chloride obtained was refluxed for additional 5 hrs. with 3-mercapto-4-N-amino-5-
(1'-naphthylmethyl)-1,2,4-triazole  (2.56 g, 0.01 M)  in pyridine (25 ml). The product
was isolated and crystall ised from ethanol. Yield 2.0g, 53%, m.p. 166oC.
(C21H18N4OS, required : C, 67.36; H, 4.85; N, 14.96; Found : C, 67.42; H, 5.02;
N, 14.99%, TLC Acetone : Benzene (3 : 7), Rf : 0.52).
Similarly, other aromatic acid chlorides have been condensed. The physical
constant are recorded in Table No. 2.
(E) Biological  evaluat ion of  3-Mercapto-4-N-Aroylamino-5-
(1'-naphthylmethyl)-1,2,4-triazoles
Antimicrobial testing was carried out as described in Part - (I), Section - I(E). The
zone of inhition of test solution are recorded in Graphical Chart No. 2.
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ANTITUBERCULAR ACTIVITY
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and Co-ordinating Facility (TAACF),
U. S. A. Primary screening of the compounds for antitubercular activity have been
conducted at 6.25 mg/ml towards Mycobacterium Tuberculosis H37Rv in BACTEC
12 B medium using the BACTEC 460 radiometric system. The compounds
demonstrating atleast >90% inhibition in the primary screen have been retested
at lower concentration towards Mycobacterium Tuberculosis H37Rv to determined
the actual minimum inhibitory concentration (MIC) in the BACTEC 460.
The antitubercular activity data have been compared with standard drug
Rifampin at 6.25 mg/ml concentration and it showed 98% inhibition. The data for
% inhibition are recorde in Table No. 2a.
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2a C6H5- C20H16N4OS 360.4 182 65 0.52 15.54 15.55
2b 2-NH2-C6H4- C20H17N5OS 375.4 152 62 0.65 18.65 18.68
2c 3-NH2-C6H4- C20H17N5OS 375.4 169 60 0.57 18.65 18.63
2d 3-C5H4N- C19H15N5OS 361.4 173 58 0.55 19.38 19.41
2e 4-Br-C6H4- C20H15N4OSBr 439.3 182 62 0.62 12.75 12.72
2f 4-Cl-C6H4- C20H15N4OSCl 394.8 166 61 0.54 14.19 14.22
2g 3,4-(NO2)2-C6H3- C20H14N6O5S 450.4 146 40 0.58 18.66 18.63
2h 4-OCH3-C6H4- C21H18N4O2S 390.4 143 55 0.55 14.35 14.38
2i 2-CH3-C6H4- C21H18N4OS 374.4 168 55 0.69 14.96 14.93
2j 3-CH3-C6H4- C21H18N4OS 374.4 162 59 0.64 14.96 14.93
2k 4-CH3-C6H4- C21H18N4OS 374.4 166 53 0.52 14.96 14.99
2l C6H5-CH=CH- C22H18N4OS 386.4 157 48 0.61 14.50 14.55
* TLC Solvent System : Acetone : Benzene : (3 : 7)
Comp.
No.
1
TABLE NO. 2 :  PHYSICAL CONSTANTS OF 3-MERCAPTO-4-N-AROYLAMINO-5-(1'-NAPHTHYLMETHYL)-
1,2,4-TRIAZOLES
Found
9
M.P.
oC
5
Calcd.
8
% of NitrogenMolecular
Formula
3
R
2
Molecular
Weight
4
Yield
%
6
Rf*
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GRAPHICAL CHART NO. 2 :  3-MERCAPTO-4-N-AROYLAMINO-5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
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COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART - II
Section - I : Antimicrobial activity of 3-Mercapto-4-N-aroylamino-5-(1'-naphthylmethyl)-1,2,4-triazoles
2b (20) 2a (17) 2l (19) 2c (17) 2a (20)
2e (19) 2k (20) 2h (15)
2f (21)
2k (19)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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NN
N
NH
O
R
SH
TAACF, Southern Research Institute
Primary Assay Summary Report
Dr. A. R. Parikh
Saurashtra University
Sample Corp Where,  R= Supplier Assay  MTb MIC %          Comment
   ID   ID Strain           Inhib
162257 PG-12 4-OCH
3
-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 45 MIC Rifampin = 0.25µg/ml
@98& inhibition
162258 PG-13 -C
5
H
4
N- Sau. Uni. Alamar H37Rv >6.25 66                "
162259 PG-14 4-Cl-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 22                "
162260 PG-15 3-CH
3
-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 17                "
162261 PG-16 4-Cl-C
10
H
12
- Sau. Uni. Alamar H37Rv >6.25 20                "
162262 PG-17 4-CH
3
-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 15                "
162263 PG-18 2-NH
2
-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 28                "
162264 PG-19 -C
6
H
5
- Sau. Uni. Alamar H37Rv >6.25 44                "
162265 PG-20 C
6
H
5
-CH=CH- Sau. Uni. Alamar H37Rv >6.25 7                "
162266 PG-21 3:4-(NO
2
)
2
-C
6
H
3
- Sau. Uni. Alamar H37Rv >6.25 0                "
162267 PG-22 4-Br-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 18                "
162268 PG-23 2-CH
3
-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 31                "
NIAID / Southern Research Institute / GWL Hansen's center / Colorado State University Proprietary Information
TABLE NO. 2a : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
CONCLUSION
Looking to the activity table, it can be concluded that no compound is
significantly active.
62
SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 5-(1'-NAPHTHYL
METHYL)-1,2,4-TRIAZOLO[3,4-b]BENZPYRAZINO[2,3-e]-4-N-AROYL-
1,3,4-THIADIAZINES
The study of thiadiazine has revealed that thiadiazines are valuable drugs
for various diseases. Compound bearing 1,2,4 triazole nucleus are still the most
prescribed drugs used in medicine. These observation led us to synthesise
thiadiazines of type (III) by condensing. 3-Mercapto-4-N-aroylamino-5-
(1'-naphthylmethyl)-1,2,4-triazoles with 2,3-dichloroquinoxaline in presence of
sodium acetate.
The constitution of the products has been established by using elemental
analyses, infrared spectroscopy and 1H nuclear magnetic resonance spectroscopy
and further confirmed by mass spectrometry86. In mass spectroscopy when
R=p-tolyl m/z = 499 indicates the moleculer weight of the compound.
All the newly synthesised compounds have been screened for their in vitro
biological assay like antibacterial activity towards Gram positive and Gram
negative bacterial strains and antifungal activity towards Aspergillus niger at a
concentration of 40 µg. The biological activities of the synthesised compounds
have been compared with standard drugs. The details have been cited in Part - I,
Section - I (E).
Type ( III )            R = Aryl
N
N
Cl
Cl
+
N N
N SH
NH
R
O
N
N
N N
N S
N
R
O
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Type Vibration                Frequency in cm-1 Ref.
mode Observed Reported
40.0
45.0
50.0
55.0
60.0
65.0
70.0
75.0
80.0
85.0
90.0
95.0
100.0
105.0
% T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cm
Alkane C-H str. (asym.) 2929 2975-2950 351
-CH3 C-H str. (sym.) 2850 2880-2860 ,,
C-H  i.p. def. 1481 1470-1435 ,,
C-H o.o.p. def. 1352 1395-1370 ,,
Aromatic C-H str. 3043 3080-3030 ,,
C=C str. 1481 1585-1480 ,,
C-H i.p. def. 1076 1125-1000 352
C-H o.o.p. def. 839 835-810 ,,
Triazole C=N str. 1598 1650-1580 353
N-N str. 1020 1050-1010 ,,
C-N str. 1166 1220-1020 ,,
Thiadiazine N-N str. 1001 1050-1010 354
C-S str. 617 700-600 ,,
N-C=O str. 1705 1690-1630 ,,
N
N
N N
N S
N
O
CH3
IR SPECTRAL STUDY OF 5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO[3,4-b]
BENZPYRAZINO[2,3-e]-4-N-(ρ-METHYLBENZOYL)-1,3,4-THIADIAZINES
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Freq. range 4000-400 cm-1 (KBr disc.)
64
65
N
N
N N
N S
N
O
OCH 3
a
b
c
d
e
f g
h
i
j
k
a'
b'
j'
k'
Internal reference : TMS
Solvent : CDCl3 + DMSO-d6
Instrument : BRUKER Spectrometer (300 MHz)
Interpretation of Spectrum :
Signal Signal Position Relative No. Multiplicity Inference
No. (d ppm) of proton
1 3.84 3H singlet Ar–OCH3
2 4.90 2H singlet –CH2–
3 6.97 2H Doublet Ar–H (bb')
4 7.41 - 7.51 4H Multiplate Ar–H (c,d,e,h)
5 7.57 2H Doublet Ar–H (kk')
6 7.68 3H Doublet Ar–H (aa'+i)
7 7.79 1H Doublet Ar–H (g)
8 7.93 2H Doublet Ar–H (jj')
9 8.37 1H Doublet Ar–H (f)
N
N
N N
N S
N
O
OCH 3
a
b
c
d
e
f g
h
i
j
k
a'
b'
j'
k'
PMR SPECTRAL STUDY OF 5 - (1 ' -NAPHTHYLMETHYL) -1 ,2 ,4 -
TRIAZOLO[3,4-b] BENZPYRAZINO[2,3-e]-4-N-(ρ-METHOXYBENZOYL)-
1,3,4-THIADIAZINES
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m/z = 500 (m-1)
N N
N S
N
N
N
O
CH3
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 5-
(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO[3,4-b]BENZPYRAZINO
[2,3-e]-4-N-AROYL-1,3,4-THIADIAZINES
(A) Preparation of 1'-Naphthyl acetohydrazide
See Part - I, Section - I(A).
(B) Preparation of Potassium 1'-naphthyl acetamido dithiocarbamate
See Part - I, Section - I (B).
(C) Preparation of 3-Mercapto-4-N-amino-5-(1'-naphthylmethyl)-
1,2,4-triazole
See Part - I, Section - I (C).
(D) Preparation of 3-Mercapto-4-N-(ρ-methylbenzoyl)amino-5-
(1'-naphthylmethyl)-1,2,4-triazole
See Part - II, Section - I(D).
(E) Preparation of 2,3-Dichloro quinoxaline130
A mixture of quinoxaline 2,3 dione (1.62g, 0.01 M), freshly distilled POCl3
(6.0 ml) and DMF (0.5 ml) was refluxed with stirring for 1.5 hrs. The cooled reaction
mixture was poured onto crushed ice with stirring and the resulting solid filtered,
washed with water and crystallised from mix. of chloroform and Hexane.
Yield 1.5g, 66%, m.p. 152-153oC.
(F) Preparat ion of  5- (1 ' -Naphthylmethyl ) -1 ,2,4- t r iazolo
[3 ,4 -b ]benzpy raz ino [2 ,3 -e ] -4 -N - (ρ-methy lbenzoy l ) -1 ,3 ,4 -
thiadiazines
A mixture of 3-Mercapto-4-N-(ρ-methylbenzoylamino)-5-
(1'-naphthylmethyl)-1,2,4-triazole (3.75g, 0.01 M),  2,3-dichloro quinoxaline
(1.99g, 0.01 M) and sodium acetate (1 g) in absolute ethanol (20 ml) was refluxed
for 10 hrs. The reaction mixture was then cooled to room temp. poured onto
69
crushed ice. The separated product was filtered washed with water and crystallised
from methanol. Yield 2.4g, 48%, m.p. 169oC. (C29H20N6OS, Required :
C, 69.58; H, 4.03; N, 16.79; Found : C, 69.61; H, 4.06; N, 16.77%, TLC
Acetone : Benzene  (4 :  6), Rf value : 0.40).
Similarly, other arylamides of type (III) were condensed with
2,3-dichloroquinoxaline. The physical constant are recorded in Table No. 3.
(G) Biological evaluation of 5-(1'-Naphthylmethyl)-1,2,4-triazolo
[3,4-b]benzpyrazino[2,3-e]-4-N-aroyl-1,3,4-thiadiazines
Antimicrobial testing was carried out as described in Part - (I), Section - I(E).
The zone of inhition of test solution are recorded in Graphical Chart No. 3.
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3a C6H5- C28H18N6OS 486.5 254 45 0.54 17.27 17.30
3b 2-NH2-C6H4- C28H19N7OS 501.6 212 58 0.61 19.55 19.52
3c 3-NH2-C6H4- C29H20N6OS 501.6 196 60 0.67 19.55 19.50
3d 3-C5H4N- C27H17N7OS 487.5 177 47 0.66 20.11 20.08
3e 4-Br-C6H4- C28H17N6OSBr 565.4 189 55 0.58 14.86 14.83
3f 4-Cl-C6H4- C28H17N6OSCl 520.9 217 62 0.55 16.13 16.15
3g 3,4-(NO2)2-C6H3- C28H16N8O5S 576.54 158 38 0.61 19.44 19.48
3h 4-OCH3-C6H4- C29H20N6O2S 516.6 165 55 0.60 16.27 16.24
3i 2-CH3-C6H4- C29H20N6OS 500.6 214 50 0.43 16.79 16.82
3j 3-CH3-C6H4- C29H20N6OS 500.6 198 57 0.69 16.79 16.81
3k 4-CH3-C6H4- C29H20N6OS 500.6 169 48 0.40 16.79 16.77
3l C6H5-CH=CH- C30H20N6OS 512.6 220 50 0.55 16.40 16.44
* TLC Solvent System : Acetone : Benzene : (4 : 6)
Comp.
No.
1
TABLE NO. 3 : PHYSICAL CONSTANTS OF 5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO
[3,4-b]BENZPYRAZINO[2,3-e]-4-N-AROYL-1,3,4-THIADIAZINES
Found
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oC
5
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8
% of NitrogenMolecular
Formula
3
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4
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%
6
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7
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GRAPHICAL CHART NO. 3  :    5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO[3,4-b]BENZPYRAZINO[2,3-e]-4-N-
AROYL-1,3,4-THIADIAZINES
7
2
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART - II
Section - II : Antimicrobial activity of 5-(1'-Naphthylmethyl)-1,2,4-triazolo[3,4-b]benzpyrazino[2,3-e]-4-N-aroyl-
1,3,4-thiadiazines
3a (10) 3b (18) 3d (19) 3e (15) 3b (20)
3e (21) 3i (18) 3i (18) 3i (17) 3e (19)
3f (19) 3j (19)
3g (20)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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PART - III
STUDIES ON 1,3,4-
THIADIAZEPINES
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INTRODUCTION
The seven membered heterocyclic ring system thiadiazepine have one
sulphur atom and two nitrogen atoms in 1,3,4 position (I).
The interes t ing b io logica l  ac t iv i t ies  of  a  novel  heterocyc le  l ike
thiadiazepines have stimulated considerable research work in recent years leading
to the synthetic utility of the derivatives of this ring system.
SYNTHETIC ASPECT
Different methods for synthesis of thiadiazepine derivatives have been
described in literature131-133.
1. Sandhu S. S. et al.134 have prepared thiadiazipine derivatives by
condensation of 2,2"-thiodiacetophenones with hydrazine hydrate in
ethylene glycol.
2. Cl.CH2.CH2.COOH cyclized with Ph.NH.NH.CS.NH2 in refluxing AcOH
containing NaOH to give 2-amino-4-phenyl-6H,7H-1,3,4 thiadiazepin-5-
one135.
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3. Sinegibskaya A. D. & co-workers136 have been synthesized by 4-amino-3-
hydrazino-1,2,4-triazoline-5-thione with α- and β-dicarbonyl compounds
then treatment of Br.CH2.CO.Ph to afford thiadiazepine.
4. Bolos Jordi et al.137 have prepared asymetric pyrrolo [2,1-b] [1,3,4]
thiadiazepine derivatives.
5. Balkrishna Kalluraya138 and co-workers have been prepared 1,3,4
thiadiazepin from 1,2,4-triazoles with acetylenic ketones and α-bromo
chalcones.
6. Brukstus A.139 have been synthesized Benzimidazo [2,1-b] pyrimido [5,4-f]
[1,3,4] thiadiazepine.
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7. Tiwari Nirupama et al.140 have synthesized 1,2,4 triazolo [3,4,-b] [1,3,4]
thiadiazepines by cyclo condensation of 4-amino-5-mercapto-1,2,4 triazole
with  2,4 pentanedione.
8. α -Chloro  ary l  hydrazones  wi th  th ioace tamide or  th ioace tamido
thiobenzamide mixture in refluxing afforded 1,3,4-thiadiazepine141.
9. All ah O.A. Ab d.142 have prepared triazolo-thiadiazepine(IX)
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Also different methods have been documented in literature143-146.
BIOLOGICAL EVALUATION
From the literature survey it was revealed that thiadiazepine derivatives
are better therapeutic agents.
1. Antitumor147,148
2. Antidepressant149,150
3. Antiviral151
4. Antiarrhythmic152
5. Antipsychotic153
6. CCK antagonists154
7. AntiHIV155
8. Gastrin Receptor antagonists156-158
9. Anticonvulsant159
Rao K. Srinivasa et al.160 have synthesised pyrazolo-[4,3-f]-1,2,4-triazolo
[3,4-b]-1,3,4-thiadiazepines (X) and tested their antibacterial, antifungal,
antiinflammatory and analgesic activities.
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Kalluraya Balakrishna161 have reported triazolo-thiadiazepine (XI) as
antibacterial and antifungal agent.
Dandia  Anshu162 and co-worker  have been prepared sp i ro
indoletriazolothiadiazepine diones and assessed for antibacterial activity.
Non-nucleoside reverse transripatase activity of some thiadiazepine have been
described by Artico Marino et al.163 silvestri Romano et al.164 have synthesized
new thiadiazipine ring system, which have found to possess anti-HIV activity.
Also, potent cycl ic urea-HIV protease inhibitors activity of some 1,3,4
thiadiazepine derivatives have been reported by Rodgers James et al.165.
Kamal Ahmed166 and co-workers have recently developed design,
synthesis and structure - activity relationship studies of some diazepines as DNA
- interactive antitumer antibiotics. Vice Susan F.167 have prepared di-indolo
thiadiazipine compounds as inflammation inhibitors, neoplasm inhibitors and
pharmaceuticals for Psoriasis treatment. Antiinflammatory activity of new
derivatives of thiadiazepine have patented by Puodzhyunjte B. A.168 et al. and
Nakchmanovich A. S.169.
Swati Sharma & co-workers170 have been synthesized thiadiazepine
derivatives as possible potential drugs for cancer metastatics, also thiadiazepine
derivatives as a anticancer agents which have been reported by Muramatsu Hiromi
et al.171. Benzothiazepinyl derivatives are reported by Ingle V. S. et al.172 as
plant pathogens.
U. V. Laddi & co-workers173 have been prepared triazolo-thiadiazepines
(XII) and tested for their antimicrobial and antituberculosis activities.
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Looking to the interesting properties of thiadiazepines it is thought
worthwhile to synthesise thiadiazepines having 1,2,4-triazole nucleus with
quinoline moiety, we have undertaken the preparation of thiadiazepines which
have been described in the following section.
SECTION - I : PREPARATION AND BIOLOGICAL EVALUATION
OF 5 - (1 ' -NAPHTHYLMETHYL) -1 ,2 ,4 -TRIAZOLO
[3 ,4 -b ] S U B S T I T U T E D  Q I N O L I N O [ 2 , 3 - f ] -
1 ,3 ,4 -THIADIAZEPINES
N
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SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF
5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO[3,4-b]SUBSTITUTED
QINOLINO[2,3-f]-1,3,4-THIADIAZEPINES
In the past years, considerable evidence has been accumulated to
demonstrate the efficiency of 1,3,4 thiadiazepines. To further assess potential of
such a class of compounds, thiadiazepine derivatives of type (IV) have been
synthesised by one pot reaction of  3-mercapto-4-N-amino-5-(1'-naphthylmethyl)-
1,2,4-triazole with substituted 2-chloro-quinoline-3-carboxaldehydes in presence
of K2CO3.
The constitution of the products has been established by using elemental
analyses, infrared spectroscopy and 1H nuclear magnetic resonance spectroscopy
and further confirmed by mass spectrometry86. In mass spectroscopy
when R=6-methoxy m/z = 424 indicates the moleculer weight of the compound.
All the newly synthesised compounds have been screened for their in vitro
biological assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H37Rv at a concentration of 6.25 mg/ml using Rifampin as
standard drug, antibacterial activity towards Gram positive and Gram negative
bacterial strains and antifungal activity towards Aspergillus niger at a
concentration of 40 µg. The biological activities of the synthesised compounds
have been compared with standard drugs. The details have been cited in Part - I,
Section - I (E).
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Type Vibration                Frequency in cm-1 Ref.
mode Observed Reported
45.0
50.0
55.0
60.0
65.0
70.0
75.0
80.0
85.0
90.0
95.0
% T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cm
Alkane C-H str. (asym.) 2922 2975-2950 351
-CH3 C-H def. (asym) 1496 1470-1435 ,,
C-H def. (sym) 1377 1395-1370 ,,
Aromatic C-H str. 3043 3080-3030 ,,
C=C str. 1496* 1520-1480 ,,
C-H i.p. def. 1056 1125-1090 352
C-H o.o.p. def. 837 835-810 ,,
Triazole C=N str. 1620 1640-1500 353
N=N str. 1589 1630-1575 ,,
C-N str. 1228 1220-1020 ,,
N-N str. 1010 1050-1010 ,,
Thiadiazepine C-S-C str. 692 700-600 354
1166 1250-1000 ,,
Ether C-O-C str. (asym) 1278 1275-1200 352
C-O-C str. (sym) 1056 1070-1000 ,,
* = overlap
N N
N S
N N
OCH3
IR SPECTRAL STUDY OF 5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO[3,4-b]-
ρ-METHOXY QINOLINO[2,3-f]-1,3,4-THIADIAZEPINES
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Freq. range 4000-400 cm-1 (KBr disc.)
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Internal reference : TMS
Solvent : CDCl3 + DMSO-d6
Instrument : BRUKER Spectrometer (300 MHz)
Interpretation of Spectrum :
Signal Signal Position Relative No. Multiplicity Inference
No. (d ppm) of proton
1 3.98 3H singlet Ar–OCH3
2 4.68 2H singlet –CH2–
3 7.09 2H Doublet qui. (2)
4 7.41 1H Doublet Ar–H (b)
5 7.44 1H Doublet Ar–H (a)
6 7.50 1H Doublet qui. (1)
7 7.52 - 7.57 2H Multiplate Ar–H (c,f,g)
8 7.67 2H Singlet Thiazepine =CH
9 7.80 1H Triplet qui. (3)
10 7.85 1H Doublet Ar–H (e)
11 8.21 1H Double Doublet Ar–H (d)
12 8.40 1H Singlet qui. (4)
13 13.76 1H Singlet –SH
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PMR SPECTRAL STUDY OF 5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO
[3,4-b]-r-METHOXY QINOLINO[2,3-f]-1,3,4-THIADIAZEPINES
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m/z = 423 . 5
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF
5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO[3,4-b]SUBSTITUTED
QINOLINO[2,3-f]-1,3,4-THIADIAZEPINES
(A) Preparation of 1'-Naphthyl acetohydrazide
See Part - I, Section - I(A).
(B) Preparation of Potassium 1'-naphthyl acetamido dithiocarbamate
See Part - I, Section - I (B).
(C) Preparation of 3-Mercapto-4-N-amino-5-(1'-naphthylmethyl)-
1,2,4-triazole
See Part - I, Section - I (C).
(D) Preparation of 5-(1'-Naphthylmethyl)-1,2,4-triazolo[3,4-b]-
6-methoxy qinolino[2,3-f]-1,3,4-thiadiazepine
To a mixture of 3-mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-
triazole  (2.56 g, 0.01 M) and 2-chloro-3-formyl-6-methoxy quinoline (2.07g,
0.01 M) in dry DMF (20 ml) was added anhydrous K2CO3 (2.0 g). The reaction
mixture stirred at 70o-80o C for 2 hr. It was cooled and poured onto crushed ice.
The product isolated and recrystallised from methanol. Yield 2g, 48%, m.p.143oC.
(C24H17N5OS, Required : C, 68.07; H, 4.05; N, 16.54; Found : C, 68.10; H,
4.02; N, 16.58%, TLC Acetone : Benzene (5 : 5), Rf : 0.58).
Similarly other susbsituted thiadiazepines were prepared. The physical
constants are recorded in Table No. 4.
(E) Biological evaluation of 5-(1'-Naphthylmethyl)-1,2,4-triazolo
[3,4-b]substituted qinolino[2,3-f]-1,3,4-thiadiazepines
Antimicrobial testing was carried out as described in Part - (I), Section - I(E).
The zone of inhition of test solution are recorded in Graphical Chart No. 4.
The antitubercular screening of the compounds have been carried
out by TAACF, Southern Research Institute, U. S. A. as described in
Part - II, Section I (E) and the percentage of inhibition data of the compounds
are recorded in Table No. 4 a.
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4a H C23H15N5S 393.4 162 62 0.43 17.80 17.83
4b 6-Cl C23H14N5SCl 427.9 124 52 0.58 16.37 16.41
4c 7-Cl C23H14N5SCl 427.9 170 62 0.62 16.37 16.38
4d 8-Cl C23H14N5SCl 427.9 144 60 0.66 16.37 16.35
4e 6-Cl, 5-F C23H13N5SFCl 445.9 178 68 0.57 15.71 15.69
4f 6:7-(Cl)2 C23H13N5SCl2 462.3 173 60 0.70 15.15 15.18
4g 6:8-(CH3)2 C25H19N5S 421.5 153 51 0.69 16.61 16.63
4h 7:8-(CH3)2 C25H19N5S 421.5 178 68 0.40 16.61 16.63
4i 6-OCH3 C24H17N5OS 423.4 143 48 0.58 16.54 16.58
4j 6-CH3 C24H17N5S 407.4 161 45 0.56 17.19 17.22
4k 7-CH3 C24H17N5S 407.4 150 53 0.49 17.19 17.21
4l 8-CH3 C24H17N5S 407.4 146 52 0.52 17.19 17.16
* TLC Solvent System : Acetone : Benzene : (5 : 5)
Comp.
No.
1
TABLE NO. 4 : PHYSICAL CONSTANTS OF 5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO[3,4-b]
SUBSTITUTED QINOLINO[2,3-f]-1,3,4-THIADIAZEPINES
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GRAPHICAL CHART NO. 4 :         5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO[3,4-b]SUBSTITUTED QINOLINO[2,3-f]-
1,3,4-THIADIAZEPINES
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COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART - III
Section - I : Antimicrobial activity of 5-(1'-Naphthylmethyl)-1,2,4-triazolo[3,4-b]substituted qinolino[2,3-f]-
1,3,4-thiadiazepines
4b (19) 4d (20) 4c (18) 4e (18) 4a (19)
4g (16) 4i (17) 4e (19)
4ki (16)
4l (19)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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TAACF, Southern Research Institute
Primary Assay Summary Report
Dr. A. R. Parikh
Saurashtra University
Sample Corp Where,  R= Supplier Assay  MTb MIC %          Comment
   ID   ID Strain           Inhib
162269 PG-24 H Sau. Uni. Alamar H37Rv >6.25 10 MIC Rifampin = 0.25µg/ml
@98& inhibition
162270 PG-25 6-Cl Sau. Uni. Alamar H37Rv >6.25 10                "
162271 PG-26 7-Cl Sau. Uni. Alamar H37Rv >6.25 0                "
162272 PG-27 8-Cl Sau. Uni. Alamar H37Rv >6.25 5                "
162273 PG-28 6-Cl, 5-F Sau. Uni. Alamar H37Rv >6.25 3                "
162274 PG-29 6:7-(Cl)
2
Sau. Uni. Alamar H37Rv >6.25 42                "
162275 PG-30 6:8-(CH
3
)
2
Sau. Uni. Alamar H37Rv >6.25 12                "
162276 PG-31 7:8-(CH
3
)
2
Sau. Uni. Alamar H37Rv >6.25 26                "
162277 PG-32 6-OCH
3
Sau. Uni. Alamar H37Rv >6.25 0                "
162278 PG-33 6-CH
3
Sau. Uni. Alamar H37Rv >6.25 0                "
162279 PG-34 7-CH
3
Sau. Uni. Alamar H37Rv >6.25 0                "
162280 PG-35 8-CH
3
Sau. Uni. Alamar H37Rv >6.25 23                "
NIAID / Southern Research Institute / GWL Hansen's center / Colorado State University Proprietary Information
N N
N S
N N
R
TABLE NO. 4a : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
CONCLUSION
Looking to the activity table, it can be concluded that no compound is
significantly active.
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PART - IV
STUDIES ON
SULFONAMIDES
91
INTRODUCTION
The discovery of sulphonamides as drug is considered to be the begining
of chemotherapeutic era by making possible a direct attack on microbial infection.
Sulphonamide was first prepared by Glemo in 1908. Gerhald Domagk in
1935 tested prontosil towards infection by homolytic streptococci and found it
very effective antibacterial which lead to the synthesis of newer molecules by
incorporating different nucleus. Sulphonamides have the general structure
R-SO2-N-R',R'' where R= organic radical, R', R'' = hydrogen or organic radical.
They are classified as aliphatic, aromatic and heterocyclic which is depending
upon the nature of R. Aromatic and heterocyclic sulphonamides have achieved
greater commercial significance. Their application in chemotherapy is so well
known that the name, 'sulpha drugs' is widely used as a general name for
sulphonamide derivatives as therapeutic agent.
THERAPEUTIC IMPORTANCE AND SYNTHETIC ASPECT
It has been now well established that sulphonamides possess valuable
biological properties including,
1. Hypoglycemic174
2. Antimalarial175
3. Antiinflammatory176
4. Herbicidal177
5. Anticoagulant178
6. Anti-HIV179
7. Antitumer180
8. Antihypertension and antiglaucoma181
92
9. Antimicrobial182
10. Antidiabetic183
11. Anticancer and antibacterial184
12. Herbicidal and crop tolerance185
13. Potasium channel inhibitor186
14. Antibacterial187
15. Endothelin188
Sulphonamides posses vast biological activities. Due to these many
sulphonamide derivatives are recently in clinical use. Some of them are shown
below.
Methazolamide Ethoxzolamide
CA inhibitor CA inhibitor
NS-398 Flosulide
COX-inhibitor COX-inhibitor
S
N N
CH3
NHCOCH3
SO2-NH2
S
N
SO2-NH2
OH5C2
O
NO2
NH SO2 CH3
O
NH SO2 CH3
F
F
O
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Chlorphenamide       Sulphanilamide Dapsone
diuretic       antibacterial antileprotic
Sulphadoxine Glyparamide
antimalarial antidiabetic
Sulphonamides continue to be used as antibacterial as they are effective,
inexpensive and free of super infection problems caused by antibiotics. Extensive
research has been carried out to enhance the activity and reduce toxicity of sulpha
drugs.
Recently two isoenzymes of cyclooxy genase have been identified  :
COX -1 and COX -2. Selective inhibition of COX-2 or dual inhibition of COX-1
and COX-2 is under discussion as a promising principle in the treatment of
inflammatory diseases. For several reasons, including increased cardiovascular
risks, the important role of COX-2 produced prostaglandins in the responce of
the mucosa to irritants and in healing and other critical aspects the accuracy of
selective COX-2 inhibition as the principle tenet is under debate.
Cl
SO2-NH2
SO2-NH2
NH2
SO2-NH2
NH2
O2S NH2
N
N
HN SO2 NH2
H3CO
H3CO
N
CH3 CH3
NHCONHO2S
Cl
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A number of substituted sulphonamides are known as anti inflammatory
agent. The first substance were diflumidone and nimesulide which was lead for
NS-398 and flosulide. Diarylmethanones such as ketoprofen, tiaprofenic acid,
tolmetine and ketorolac are used in the therapy of inflammation.
The objective of this study was to correlate the structural parameters with
the inhibitory potency and the enzyme selectivity, i.e. to evaluate the significance
of sulphonamides as a latest biologically active compounds.
Moreover Gerd Dannhardt et al.189 have described the synthesis
and COX-1 / COX-2 inhibitory activity of some sulphonamides.
COX-1 and COX-2 inhibitors
Claudiu T. Supuran et al.190 have documented some CA inhibitors. CA is
concerning to Von Hippel-Lindau tumers, Progressive polycystic kidney disease,
Carcinomas of the pancreas or Autoimmune/idiopathic chronic pancreatities, it
appeared of great interest to further explore the connections between CAs and
tumours.
Carbonic Anhydrase (CA) isozyme inhibitors
CH3
O NH So2 CH3 NH So2 CH3
SO2 NH O CH3F
F
F F
X
X  =  H, F, Br
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Stein Philip P. et al.191 have reported arylsulphonaidopiperidones and
also tested biological activity, such as inhibitors of Factor Xa.
Dhanak Dashyant et al.192 synthesise some sulphonamides as antagonists
of urotensin II.
Antagonist of urotensin - II
CONTRIBUTION FROM OUR LABORATORY
Parikh and co-workers have evaluated several sulphonamide derivatives
having the general formula R-SO2-NH-R' where R=phenyl, substituted phenyl,
α-and β-naphthyl and R'=2,4-disubstituted s-triazine193-195, 4-(1'-aryl-3'-
chloro-4'-methyl-2 '-azet idinone-4'-yl)-phenyl196, 3-chloro-4-(p-chloro/
bromophenyl)-2-azetidinone197, 4-(2'-aryl-1,3,4-oxadiazole-5'-yl)-phenyl198,
5-pyridyl-1,3,4-oxadiazole199, 1,4-bis amino phthalazine200 and 6-carboxy
penicillic acid201 moieties in search of possible antimicrobialagents.
General structure for above references are as under.
SO2 NHO
O
O
CH3
CH3
CH3
Cl
O
N
CH3
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R = Phenyl, Substituted phenyl, α and β-naphthyl etc
Parekh et al.202 have synthesised some new sulphonamides as novel
bioactive compounds derived from benzimidazole. John et al.203 have prepared
some sulphonamide derivatives as potent antidiabetic agent. More recently Mishra
et al.204 and  O. A. Fathalla205 have reported some novel sulphonamides as
antifungal, pesticidal and anti cancer agent.
Keeping in view of these valid observations prompted us to synthesis
sulphonamides bearing triazole moiety. So as to enhance the overall activities.
PART - I : PREPARATION AND BIOLOGICAL EVALUATION OF
3-MERCAPTO-4-N-ARYLSULPHONAMIDO-5-
(1' -NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
N
N
N
CH3
NHR SO2-Ph
;
S
N
CH3
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N
N
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CH3
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N N
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N N
R
N
CH3 N
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NH CO
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CONHNHCH3
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N
NH NH NH2
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SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-
4 - N - A R Y L S U L P H O N A M I D O - 5 - ( 1 ' - N A P H T H Y L M E T H Y L ) -
1,2,4-TRIAZOLES
With an aim to getting better therapeutic agent and considering the
association of various biological activity with triazole nuclei, the preparation of
aryl sulphonamide of type (V) have been undertaken by the condensation of
3-mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-triazole with different
substituted arylsulphonyl chlorides in dry pyridine.
The constitution of the products has been established by using elemental
analyses, infrared spectroscopy and 1H nuclear magnetic resonance spectroscopy
and further confirmed by mass spectrometry86. In mass spectroscopy
when R=p-tolyl m/z =411 indicates the moleculer weight of the compound.
All the newly synthesised compounds have been screened for their in vitro
biological assay like antibacterial activity towards Gram positive and Gram
negative bacterial strains and antifungal activity towards Aspergillus niger at a
concentration of 40 mg. The biological activities of the synthesised compounds
have been compared with standard drugs. The details have been cited in Part - I,
Section - I (E).
N
N
N
SH
NH2
N
N
N SH
NH
SO2
R
Type ( V )            R = Aryl
R-SO 2-Cl
Pyridine
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Type Vibration                Frequency in cm-1 Ref.
mode Observed Reported
30.0
35.0
40.0
45.0
50.0
55.0
60.0
65.0
70.0
75.0
80.0
85.0
90.0
95.0
100.0
105.0
% T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cm
Alkane C-H str. (asym.) 2920 2975-2950 351
-CH3 C-H str. (sym.) 2862 2880-2860 ,,
C-H def. (asym) 1409 1470-1435 ,,
C-H def. (sym) 1336 1385-1370 ,,
Aromatic C-H str. 3039 3080-3030 ,,
C=C str. 1496 1520-1480 ,,
C-H i.p. def. 1097 1125-1090 352
C-H o.o.p. def. 819 835-810 ,,
Triazole C=N str. 1512 1640-1500 353
N=N str. 1566 1630-1575 ,,
C-N str. 1238 1220-1020 ,,
N-N str. 1004 1050-1010 ,,
Sulphonamide N-H str. 3417 3550-3250 354
N-H def. 1566* 1650-1580 ,,
C-N str. 1217 1220-1020 ,,
S=O str. (asym.) 1336* 1380-1300 ,,
S=O str. (sym.) 1174 1180-1140 ,,
* = overlap
N
NN
SH
NH
O2S
CH3
IR SPECTRAL STUDY OF 3-MERCAPTO-4-N-(ρ-TOLYL)-SULPHONAMIDO-
5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Freq. range 4000-400 cm-1 (KBr disc.)
98
99
N
NN
SH
NH
O2S
CH3
a b
cd
e
f g
hh'
ii'
NNN
SH
NH
O2S
CH3
PMR SPECTRAL STUDY OF 3-MERCAPTO-4-N-(r-TOLYL) SULPHONAMIDO-
5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLE
100
1
0
1
m/z = 410 . 5 (m + 1)
N N
N SH
NH SO 2
CH3
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-
4-N-ARYLSULPHONAMIDO-5- (1 ' -NAPHTHYLMETHYL) -1 ,2 ,4 -
TRIAZOLES
(A) Preparation of 1'-Naphthyl acetohydrazide
See Part - I, Section - I(A).
(B) Preparation of Potassium 1'-naphthyl acetamido dithiocarbamate
See Part - I, Section - I (B).
(C) Preparation of 3-Mercapto-4-N-amino-5-(1'-naphthylmethyl)-
1,2,4-triazole
See Part - I, Section - I (C).
(D) Preparation of 3-Mercapto-4-N-(ρ-Methylphenyl)sulphonamido-
5-(1'-naphthylmethyl)-1,2,4-triazole
A mixture of ρ-methlphenylsulphonyl chloride (1.91g, 0.01 M) and
3-mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-triazole  (2.56 g, 0.01 M)  in
absolute alcohol was refluxed for 5 hrs. in presence of pyridine (5 ml). The
reaction mixture was poured onto crushed ice when a solid seperated out which
was filtered, washed with water and crystallised from ethanol. Yield 2.3g, 57%,
m.p. 215oC. ( C20H18N4O2S2, Recquired : C, 58.52; H, 4.42; N, 13.65; Found
: C, 58.57; H, 4.46; N, 13.60%, TLC : Acetone : Benzene (3.5 : 6.5), Rf : 0.51).
Similarly, other thiadiazoles were prepared and the physical data are
recorded in Table No. 5.
(E) Biological evaluation of 3-Mercapto-4-N-Arylsulphonamido-5-
(1'-naphthylmethyl)-1,2,4-triazoles
Antimicrobial testing was carried out as described in Part - (I), Section - I(E).
The zone of inhition of test solution are recorded in Graphical Chart No. 5.
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5a 4-CH3-C6H4- C20H18N4O2S2 410.5 195 48 0.51 13.65 13.68
5b 4-Br-C6H4- C19H15N4O2S2Br 475.3 235 52 0.47 11.79 11.81
5c 4-NHCOCH3-C6H4- C21H19N5O3S2 453.5 228 64 0.57 15.44 15.41
5d 4-Cl,3-COOH -C6H3- C20H15N4O4S2Cl 474.9 195 58 0.68 11.80 11.84
5e 4-Cl-C6H4- C19H15N4O2S2Cl 430.9 185 55 0.54 13.00 12.97
5f 3-CH=CH-C6H5- C21H18N4O2S2 422.5 220 50 0.62 13.26 13.29
5g 3-COOH -C6H5- C20H16N4O4S2 440.4 230 62 0.70 12.72 12.76
5h 2,4-(Cl)2-C6H3- C19H14N4O2S2Cl2 465.3 250 45 0.74 12.04 12.03
5i 4-F-C6H4- C19H15N4O2S2F 414.4 198 55 0.56 13.52 13.55
5j 3-COOH, 4-OH, -C6H3- C20H16N4O5S2 456.4 220 52 0.62 12.27 12.30
5k 3-COOH, 4-OCH3 -C6H3- C21H18N4O5S2 470.5 225 39 0.49 11.91 11.94
5l 3-COOH, 4-NO2 -C6H3- C20H15N5O6S2 485.4 200 62 0.68 14.43 14.42
* TLC Solvent System : Acetone : Benzene : (3.5 : 6.5)
Comp.
No.
1
TABLE NO. 5   : PHYSICAL CONSTANTS OF 3-MERCAPTO-4-N-ARYLSULPHONAMIDO-5-(1'-NAPHTHYL
METHYL)-1,2,4-TRIAZOLES
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5
Calcd.
8
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3
R
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4
Yield
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COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART - IV
Section - I : Antimicrobial activity of 3-Mercapto-4-N-arylsulphonamido-5-(1'-naphthylmethyl)-1,2,4-triazoles
5g (19) 5c (18) 5b (19) 5c (15) 5e (18)
5j (20) 5j (17) 5e (16)
5g (17)
5k (17)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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PART - V
STUDIES ON
4-ARYLTRIAZOLES
SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-
4-N-ARYL-5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
During the past years, considerable evidences have been accumulated to
demonstrate the potential of triazole derivatives incorporating variety of biological
properties. Triazole derivatives of type (VI) have been prepared by the dry heating
of potassium-3-isonicotinoyl-dithiocarbamate with different aromatic amines until
the evolution of H2S ceased.
The constitution of the products has been established by using elemental
analyses, infrared spectroscopy and 1H nuclear magnetic resonance spectroscopy
and further confirmed by mass spectrometry86. In mass spectroscopy when
R=p-tolyl m/z = 332 indicates the moleculer weight of the compound.
All the newly synthesised compounds have been screened for their in vitro
biological assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H37Rv at a concentration of 6.25 mg/ml using Rifampin as
standard drug, antibacterial activity towards Gram positive and Gram negative
bacterial strains and antifungal activity towards Aspergillus niger at a
concentration of 40 mg. The biological activities of the synthesised compounds
have been compared with standard drugs. The details have been cited in Part - I,
Section - I (E).
NH NH
S KO S K2CO3
Type ( VI )            R = Aryl
- +
+R- NH2
N N
N SH
R
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Type Vibration                Frequency in cm-1 Ref.
mode Observed Reported
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
110.0
% T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cm
Alkane C-H str. (asym.) 2949 2975-2950 351
-CH3 C-H str. (sym.) 2839 2880-2860 ,,
C-H def. (asym.) 1423 1470-1435 ,,
C-H def. (sym.) 1392 1395-1370 ,,
Aromatic C-H str. 3047 3080-3030 ,,
C=C str. 1548 1585-1480 ,,
1510 1520-1480
C-H i.p. def. 1056 1070-1000 352
C-H o.o.p. def. 810 835-810 ,,
Triazole S-H str. 2362 2400-2300 353
C=N str. 1596 1612-1593 ,,
N-N str. 1033 1050-1010 ,,
C-N str. 1218 1220-1020 ,,
C-S str. 671 700-600 ,,
Ester C-O-C str. 1274 1275-1200 352
1056* 1070-1000 ,,
* = overlap
N
N
N
SH
H3CO
IR SPECTRAL STUDY OF 3-MERCAPTO-4-N- (ρ -ANISYL) -5- (1 ' -
NAPHTHYLMETHYL)-1,2,4-TRIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Freq. range 4000-400 cm-1 (KBr disc.)
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109
N N
N SH
OCH3
a
b
c
d
e
f g
h
i
a'
b'
Internal reference : TMS
Solvent : CDCl3 + DMSO-d6
Instrument : BRUKER Spectrometer (300 MHz)
Interpretation of Spectrum :
Signal Signal Position Relative No. Multiplicity Inference
No. (d ppm) of proton
1 2.38 3H singlet Ar–OCH3
2 4.28 2H singlet –CH2–
3 6.89 1H Doublet Ar–H (h)
4 6.98 2H Doublet Ar–H (aa')
5 7.19 1H Doublet Ar–H (d)
6 7.21 1H Doublet Ar–H (c)
7 7.24 1H Doublet Ar–H (i)
8 7.45 2H Doublet Ar–H (bb')
9 7.73 1H Doublet Ar–H (e)
10 7.81-7.85 2H Multiplate Ar–H (f,g)
11 11.1 1H Broad Band –SH
N N
N SH
OCH3
a
b
c
d
e
f g
h
i
a'
b'
P M R  S P E C T R A L  S T U DY  O F  3 - M E R C A P T O - 4 - N - ( r - A N I S Y L ) - 5 -
(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLE
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1
1
1
N N
N SH
CH3
m/z = 331 . 4
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-
4-N-ARYL-5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
(A) Preparation of 1'-Naphthyl acetohydrazide
See Part - I, Section - I(A).
(B) Preparation of Potassium 1'-naphthyl acetamido dithiocarbamate
See Part - I, Section - I (B).
(C) Preparat ion  of  3-Mercapto-4-N-(ρ-methoxy)phenyl -5-
(1'-naphthylmethyl)-1,2,4-triazole
A suspension of the Potassium 1'-naphthyl acetamido dithiocarbamate
(2.76g, 0.01 M), ρ-anisidine (1.23g, 0.01M) and water (2 ml) was refluxed with
stirring for 2 hours. A homogenous solution resulted with change in colour to
green. It was diluted with water and acidify with gl. acetic acid gave white
precipitate. This product was filtered washed with cold water and crystallised
in ethanol. Yield 2.1g, 61%, m.p. 169oC. ( C20H17N3OS, Required : C, 69.14;
H, 4.93; N, 12.09; Found : C, 69.21; H, 5.03; N, 12.06%, TLC Acetone : Benzene
(4.5 : 5.5), Rf : 0.47.
Similarly, other thiadiazoles were prepared and the physical data are
recorded in Table No. 6.
(D) Biological  evaluat ion of  3-Mercapto-4-N-ar yl -5-
(1'-naphthylmethyl)-1,2,4-triazoles
Antimicrobial testing was carried out as described in Part - (I), Section - I(E).
The zone of inhition of test solution are recorded in Graphical Chart No. 6.
The antitubercular screening of the compounds of type (VI) have been
carried out by TAACF, Southern Research Institute, U. S. A. as described
in Part - II, Section I (E) and the percentage of inhibition data of the compounds
are recorded in Table No. 6 a.
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6a C6H5- C19H15N3S 317.4 133 65 0.57 13.24 13.27
6b 2-Cl-C6H4- C19H14N3SCl 351.8 168 65 0.59 11.94 11.92
6c 3-Cl-C6H4- C19H14N3SCl 351.8 165 62 0.62 11.94 11.91
6d 4-Cl-C6H4- C19H14N3SCl 351.8 155 57 0.47 11.94 11.91
6e 3,4-(Cl)2-C6H3- C19H13N3SCl2 386.2 138 55 0.70 10.88 10.92
6f 2,3-(CH3)2-C6H3- C21H19N3S 345.4 215 54 0.54 12.16 12.19
6g 2,4-(CH3)2-C6H3- C21H19N3S 345.4 144 56 0.61 12.16 12.19
6h 3-OCH3-C6H4- C20H17N3OS 347.4 146 63 0.43 12.09 12.12
6i 4-OCH3-C6H4- C20H17N3OS 347.4 169 61 0.47 12.09 12.06
6j 2-CH3-C6H4- C20H17N3S 331.4 153 61 0.53 12.68 12.70
6k 3-CH3-C6H4- C20H17N3S 331.4 148 62 0.59 12.68 12.64
6l 4-CH3-C6H4- C20H17N3S 331.4 173 60 0.66 12.68 12.71
* TLC Solvent System : Acetone : Benzene : (4.5 : 5.5)
Comp.
No.
1
TABLE NO. 6  : PHYSICAL CONSTANTS OF 3-MERCAPTO-4-N-ARYL-5- (1 ' -NAPHTHYLMETHYL)-
1,2,4-TRIAZOLES
Found
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COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART - V
Section - I : Antimicrobial activity of 3-Mercapto-4-N-aryl-5-(1'-naphthylmethyl)-1,2,4-triazoles
6j (19) 6a (16) 6b (19) 6a (16) 6j (20)
6b (18) 6h (20) 6e (15) 6l (19)
6c (17) 6k (17)
6h (16)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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[B]
STUDIES ON 1,3,4-
THIADIAZOLES
118
INTRODUCTION
Thiadiazole have occupied an important place in drug industry. It is
documented in the literature that thiadiazole system contains the following
members : The 1,2,3 Thiadiazoles (I), 1,2,4-Thiadiazoles (II), 1,3,4 Thiadiazoles
(III) and 1,2,5-Thiadiazoles (IV) and their benzo derivatives. Most of the published
work so far, is on 1,3,4-Thiadiazoles.
1,3,4-Thiadiazoles were first described in 1882 by Fishcer and further
developed by Busch and his co-workers. The advert of sulfar drugs and their
discovery of mesoionic compounds greatly accelerated the rate of progress in
the field of thiadiazoles.
Various 3-substituted-4-amino-5-mercapto-1,2,4-triazoles have been
repor ted to possess analgesic, antibacterial, antifungal, antiinflammatory,
antitubercular, antiviral, herbicidal and sedative properties 206-211. The amino
and mercapto groups of these compounds serve as readily accessible nucleophilic
centers for the preparation of N-bridged heterocyclies. The 1,3,4-thiadiazoles
exhibit broad spectrum of biological activities, possibly due to the presence of
toxophoric >N-C-S moiety212. They find applications as antibacterials,
antitumour and antiinflammatory agents, pesticides, herbicides, dyes lubricants
and analytical reagents213. The 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole derivatives
obtained by fusing the bio-labile. 1,2,4-triazole and 1,3,4-thiadiazole rings
together are reported to possess antibacterial, antifungal, antiinflammatory, CNS
S S
N
N
S
N N
S
NN
N
N
( I ) ( II ) ( III ) ( IV )
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depressant, hypocholesteremic, antiviral, analgesic, anthelmintic, herbicidal and
plant growth regulatory effects214.
It is also observed that incorporation of aryloxymethyl substituent and the
halogen atom into the heterocyclic ring systems augments the biological activities
considerably215-216. Further, it has been reported that many biologically active
natural and synthetic products have interesting molecular symmetry217.
Recentlysome thiadiazoles having an excellent biological activity are reported
which are explained bellow.
The literature of 1,3,4-thiadiazoles have been extensively reviewed as
under.
1947 Sandstrom218
1951 Sherman219
1952 Bambas220
1977 F. Kurzer221
1979 M. Davis222
1979 Campbell223
SYNTHETIC ASPECT
Several publication and potents224 described the synthesis of
1,3,4-thiadiazoles.
1. In 1982 Bahadur et al.225 claimed that thiosemicarbazides in sulphuric
acid cyclised to respective thiadiazole.
2. Chande Madhukar et al.226 have been prepared spiro type of 1,3,4
thiadiazole from amino mercapto triazole.
N
N N
SHR'
NH2
N
N N
R'
N
S
O
N
O
R
R' = Me, Et
R = H, Cl( V )
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3. Presence of catalyst POCl3, the 1,3,4-thiadiazole derivatives can be
prepared by Sun, Xiao-Wen et al.227 and Barghash A. M.228.
4. Q. Bano & co-workers229 have been prepared 6-phenylamino 1,3,4-
thiadiazoles. from N-amino-mercapto-1,2,4-triazole.
5. Jag Mohan et al.230 have been prepared thiadiazole derivative from amino
mercapto triazole and aryl aldehyde.
6. Microwave irradiation used for the preparation of thiadiazole using DMf
as an energy transfer medium by Kidwai Mazaahir et al.231.
7. 1,3,4-Thiadiazolidines can be prepared through the intramolecular
Mannich reaction by Yu, Jian-Xian et al.232.
8. Nakao Hayami et al.233 have synthesised 3,5-dichloro-2-methoxy-N-(5-
trifluoromethyl-1,3,4- thiadiazole-2-yl)benzamide from 3,5-dichloro-2-
methoxy-benzoylchlorde which has shown fungicidal activity against
Venturia inequalis.
9. M. K. Albrahim et al.234 synthesise thiadiazole from hydrazinyl chloride.
N
N
SH
N
NH2
N
N
Me
N
CO2H
R
+
N
N
N
Ph N
S
N
N
H3C
N
R
( VI )
R = 2,3,4-Cl
2,3,4-Br
3,4-Me
2,4-MeO
Ph
POCl3
X
N
NH
NH – N C
Cl
CO–R
( VII ) X
N
NH
N
N
S
N–CO–R'
H3C–C
O
X = H,Cl
R'–CO–NCS
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BIOLOGICAL IMPORTANCE
1,3,4-Thiadiazoles have wide application in many fields. The earliest uses
were in the pharmaceutical area as antibacterials with known sulfonamide drugs.
Some of the later uses are as antitumor and antiinflammatory agents, pesticides,
dyes, lubricants and analytical reagents.
1,3,4-Thiadiazole-2-sulphonamides came into focus due to the discovery
by Miller et al.235 of carbonic anhydrase inhibiting effect of 2-Acetamido-1,3,4-
thiadiazole-5-sulfonamide. This compound has been extensively investigated for
its effect on salt excretion and eye pressure and also as an anti convulsant236.
cefazedone (VIII) is a thiadiazole analog of cephalosporanic acid useful as an
antibacterial237.
Synthesis and in vivo antibacterial an antifungal properties of some 3,6-
diaryl-5,6-dihydro-triazolo [3,4-b]-1,3,4 thiadiazoles have been documented by
Wang Zhong-Yi & coworkers238 (IX).
N
Cl
O
Cl
O
N
H
N
O
H H
S
COOH
S
N N
S
CH3
( VIII )
R
N N
HN
N S
R'
R' = 2–MeO
= 4–NO2
= 4-Me2–N
R = 2–MeO
= 4–MeO
( IX )
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Synthesis and activity against leishmania amazonensis promastigotes and
amastigotes have been reported by da Silva Edson F.239.
Literature survey reveals that various thiadiazoles have resulted in many
potential drugs and are known to exhibit a broad spectrum of biological activity
such as
1. Herbicidal240,241
2. Insecticidal242,243
3. Pesticidal244
4. Amoebicidal245
5. Antiviral246
6. CNS depressant247
7. Antibacterial248-249
8. Antagonist agent250
9. Antifungal251-256
10. Hypoglycemic257
11. Antiinflammatory258-261
12. Antimicrobial262-266
13. Antihypertensive267,268
14. Antiaflatoxigenic269
15. Algaecides & antifouling270
16. Antitubercular271
17. Antipyretic272
18. Anthelmintic273
S
N+ N
NH Ph
R
R1
Ph Cl
-
R = H, Me, OMe, NO2, F, Cl
R1 = OME, NO2, Cl, Br
( X )
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19. Antischistosomal274
20. Antitumor275
CONTRIBUTION FROM OUR LABORATORY
Parikh et al. have used substituted thiazolidinone276, substituted
benzthiazole and s-triazine277,278, 4'-pyridyl279 moieties at 5-position (y) of
1,3,4-thiadiazole ring. In above synthesised thiadiazole, 2-position (x) was
substituted by aryl, amino as s-triazine280. H. H. Parekh and co-workers have
synthesised 1,3,4-thiadiazole having dapson281,282, bis moiety at 5-position
(y) and benzalamino, benzoyl amino and sulphonamio283 moiety substituted at
2-position (x). General structure for above references is as under :
Parekh et al.284 have been synthesised and biologically evaluate some
1,3,4-thiadiazoles which is reported and structure is given bellow.
X
,
- CH2 - NH
X =
N
Y =
O
S
R
,
S
N N
Y
, ,
- C = O
,
S
N N N
NS NH - CH2 - C
- N = CH
NH - CH2 - C - NH - R
O
HN - R
,
O
( XI )
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Jin Fuqliang et al.285 have synthesised some new thiadiazole derivatives
used as antiulcers. Turner Steven286 and co-workers have prepared thiadiazole
derivatives as treatment of CMV infection. Desai K. R.287 and et al. have
synthesised 2-(2,4,6-tr ichlorophenoxymethyl)-5-amino-1,3,4-thiadiazole
derivatives as antibacterial and antimycobacterial activity. Song Yuntao288 have
been synthesized thiadiazole derivatives and tested their cyclooxygenase
2-inhibitors activity. Several co-workers synthesized thiadiazole derivatives having
antiinflammatory289,290, fungicidal291-294, plant growth regulators295,
insecticidal296, antibacterial297 and metalloproteinase Inhibitor298, inhibitors
of cysteine299 activity.
A triazolo-thiadiazole system resembling biguanide structure may be
responsible for the diverse biological activities. It was contemplated to synthesise
some 1,3,4-thiadiazoles in search of agents possessing higher biological activity
with least side effect, which have been discussed as under :
PART - I : STUDIES ON TRIAZOLOTHIADIAZOLES
PART - II : STUDIES ON N-THIOUREDO-1,2,4-THIADIAZOLES
PART - III : MICROWAVE ENHANCED SYNTHESIS OF
1,3,4-THIADIAZOLES
CH 3
CH 3
S
N N
N H CO-Ph
C H 3
( XII )
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PART - I
STUDIES ON
TRIAZOLOTHIADIAZOLES
SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 2-ARYL-4-
(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLES
Thiadiazole derivatives are endowed with variety of pharmacodynamic
activities. Looking to the interesting properties of thiadiazoles, it was considered
wor thwhile to synthesise a series of 2-aryl-4-(1'-naphthylmethyl)-1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazoles of type (VII) for obtaining biologically potent
agents. Thiadiazoles of type (VII) have been synthesized by cyclocondensation
of 4-amino-3-mercapto-5-pyridin-4'-yl-[1,2,4] triazole with different aromatic
acids in presence of POCl3.
The constitution of the products has been established by using elemental
analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
confirmed by mass spectrometry86. In mass spectroscopy when R=p-anisyl
m/z = 373 indicates the moleculer weight of the compound.
All the newly synthesised compounds have been screened for their in vitro
biological assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H37Rv at a concentration of 6.25 mg using Rifampin as standard
drug, antibacterial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards Aspergillus niger at a concentration of
40 mg. The biological activities of the synthesised compounds have been
compared with standard drugs. The details have been cited in Part - I,
Section - I (E).
N
N
N SH
NH2
R-COOH
POCl3
N
N
N
S
N
R
Type ( VII )            R = Aryl
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Type Vibration                Frequency in cm-1 Ref.
mode Observed Reported
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
110.0
% T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cm
Alkane C-H str. (asym.) 2929 2975-2950 351
-CH3 C-H str. (sym.) 2833 2880-2860 ,,
C-H def. (asym.) 1467 1470-1435 ,,
C-H def. (sym.) 1394 1395-1370 ,,
Aromatic C-H str. 3049 3080-3030 ,,
C=C str. 1575 1585-1480 ,,
C-H i.p. def. 1116 1125-1090 352
1033 1070-1000 ,,
C-H o.o.p. def. 835 835-810 ,,
Triazole C=N str. 1604 1612-1593 353
C-N str. 1313 1360-1310 ,,
C-N-C str. 1174 1146-1132 ,,
N-N str. 1033 1050-1010 ,,
Ether C-O-C str. (asym.) 1275 1275-1200 352
C-O-C str. (sym.) 1033* 1070-1000 ,,
Thiadiazole C-S-C str. 686 720-570 ,,
* = overlap
N
N
N
S
N
OCH 3
IR SPECTRAL STUDY OF 2-(ρ-ANISYL)-4-(1'-NAPHTHYL METHYL)-1,2,4-
TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Freq. range 4000-400 cm-1 (KBr disc.)
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N
N
N
S
N
OCH3
a
b
cd
e
f
g h
i
a'
b'
Internal reference : TMS
Solvent : CDCl3 + DMSO-d6
Instrument : BRUKER Spectrometer (300 MHz)
Interpretation of Spectrum :
Signal Signal Position Relative No. Multiplicity Inference
No. (d ppm) of proton
1 3.87 3H singlet Ar–OCH3
2 4.90 2H singlet –CH2–
3 6.97 2H Doublet Ar–H (bb')
4 7.47 1H Doublet Ar–H (h)
5 7.54 1H Doublet Ar–H (d)
6 7.57 - 7.59 2H Multiplate Ar–H (c,e)
7 7.71 2H Doublet Ar–H (a,a')
8 7.79 1H Doublet Ar–H (i)
9 7.85 1H Doublet Ar–H (g)
10 7.38 1H Doublet Ar–H (f)
N
N
N
S
N
OCH3
a
b
cd
e
f
g h
i
a'
b'
PMR SPECTRAL STUDY OF 2-(ρ-ANISYL)-4-(1'-NAPHTHYL METHYL)-1,2,4-
TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLE
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1
2
9
m/z = 372 . 4
N N
N S
N O
CH3
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-ARYL-4-
(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLES
(A) Preparation of 1'-Naphthyl acetohydrazide
See Part - I, Section - I(A).
(B) Preparation of Potassium 1'-naphthyl acetamido dithiocarbamate
See Part - I, Section - I (B).
(C) Preparation of 3-Mercapto-4-N-amino-5-(1'-naphthylmethyl)-
1,2,4-triazole
See Part - I, Section - I (C).
(D) Preparat ion of  2- (ρ-Anisy l ) -4 - (1 ' -naphthylmethyl ) -1 ,2,4-
triazolo[3,4-b]-1,3,4-thiadiazole
A mixture of ρ-anisic acid (1.52g, 0.01 M) and 3-mercapto-4-N-amino-5-
(1'-naphthylmethyl)-1,2,4-triazole  (2.56 g, 0.01 M)  in POCl3 (20 ml) was refluxed
for 10 hrs. The reaction mixture was poured onto crushed ice when a solid
seperated out which was filtered, washed with water and crystallised from
methanol. Yield 2.1g, 56%, m.p. 145oC. ( C21H16N4OS, Recquired : C, 67.72;
H, 4.33; N, 15.04; Found : C, 67.70; H, 4.40; N, 15.07%, TLC Acetone : Benzene
(4 : 6), Rf  : 0.69).
Similarly, other thiadiazoles were prepared and the physical data are
recorded in Table No. 7.
(E) Biological evaluation of 2-Aryl-4-(1'-naphthylmethyl)-1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazoles
Antimicrobial testing was carried out as described in Part - (I), Section - I(E).
The zone of inhition of test solution are recorded in Graphical Chart No. 7.
The antitubercular screening of the compounds of type (VII) have been
carried out by TAACF, Southern Research Institute, U. S. A. as described in Part
- II, Section I (E) and the percentage of inhibition data of the compounds are
recorded in Table No. 7 a.
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7a 3-C5H4N- C19H13N5S 343.4 >200 42 0.48 20.39 20.41
7b 2-NH2-C6H4- C20H15N5S 357.4 138 65 0.56 19.59 19.55
7c 3-NH2-C6H4- C20H15N5S 357.4 162 67 0.47 19.59 19.55
7d 4-NH2-C6H4- C20H15N5S 357.4 135 63 0.62 19.59 19.57
7e 4-Br-C6H4- C20H13N4SBr 421.3 159 50 0.60 13.30 13.33
7f 4-Cl-C6H4- C20H13N4SCl 376.8 168 42 0.57 14.87 14.90
7g 2,4-(OH)2-C6H3- C20H14N4O2S 374.4 184 57 0.51 14.96 14.99
7h 3,4-(NO2)2-C6H3- C20H12N6O4S 432.4 155 40 0.54 19.44 19.42
7i 2-OH-C6H4- C20H14N4OS 358.4 129 54 0.49 15.63 15.66
7j 4-OCH3-C6H4- C21H16N4OS 372.4 145 56 0.69 15.04 15.07
7k 3-CH3-C6H4- C21H16N4S 356.4 185 62 0.52 15.72 15.76
7l -CH=CH-C6H5 C22H16N4S 368.4 143 60 0.56 15.21 15.19
* TLC Solvent System : Acetone : Benzene : (4 : 6)
Comp.
No.
1
TABLE NO. 7  : PHYSICAL CONSTANTS OF 2-ARYL-4-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO
[3,4-b]-1,3,4-THIADIAZOLES
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GRAPHICAL CHART NO. 7 :  2-ARYL-4-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLES
1
3
3
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART - I
Section - I : Antimicrobial activity of 2-Aryl-4-(1'-naphthylmethyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles
7i (21) 7d (18) 7g (17) 7d (18) 7g (18)
7k (19) 7h (16) 7l (17) 7e (16) 7i (19)
7h (15)
7j (17)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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TAACF, Southern Research Institute
Primary Assay Summary Report
Dr. A. R. Parikh
Saurashtra University
Sample Corp Where,  R= Supplier Assay  MTb MIC %          Comment
   ID   ID Strain           Inhib
162246 PG-1 4-OCH
3
-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 62 MIC Rifampin = 0.25µg/ml
@98& inhibition
162247 PG-2 2:4-(OH)
2
-C
6
H
3
- Sau. Uni. Alamar H37Rv >6.25 0                "
162248 PG-3 -C
5
H
4
N- Sau. Uni. Alamar H37Rv >6.25 32                "
162249 PG-4 3-NH
2
-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 0                "
162250 PG-5 4-NH
2
-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 21                "
162251 PG-6 2-NH
2
-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 0                "
162252 PG-7 3:4-(NO
2
)
2
-C
6
H
3
- Sau. Uni. Alamar H37Rv >6.25 0                "
162253 PG-8 C
6
H
5
-CH=CH- Sau. Uni. Alamar H37Rv >6.25 0                "
162254 PG-9 2-OH-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 57                "
162255 PG-10 4-Cl-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 54                "
162256 PG-11 4-Br-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 70                "
NIAID / Southern Research Institute / GWL Hansen's center / Colorado State University Proprietary Information
N
N
N
S
N
R
TABLE NO. 7a : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
CONCLUSION
Looking to the activity table, it can be concluded that no compound is
significantly active.
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SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 2-ARYL-4-
(1'-NAPHTHYLMETHYL)-2,3-DIHYDRO-1,2,4-TRIAZOLO[3,4-b]-1,3,4-
THIADIAZOLES
Thiadiazo le  der iva t ives  are  assoc ia ted wi th  broad spec t rum of
pharmacological activity. In view of these finding it appeared of interest to
synthesise newer thiadiazole derivatives, with better potency. Thiadiazoles of type
(VIII) have been prepared by the condensation of different aromatic aldehydes
with 3-mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-triazole in the presence
of r-TS-OH (r-toluene sulphonic acid) as a catalyst, as shown in reaction Scheme
(VIII).
The constitution of the products has been established by using elemental
analyses, infrared spectroscopy and 1H nuclear magnetic resonance spectroscopy
and further confirmed by mass spectrometry86. In mass spectroscopy
when R=p-anisyl m/z = 375 indicates the moleculer weight of the compound.
All the newly synthesised compounds have been screened for their in vitro
biological assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H37Rv at a concentration of 6.25 mg/ml using Rifampin as
standard drug, antibacterial activity towards Gram positive and Gram negative
bacterial strains and antifungal activity towards Aspergillus niger at a
concentration of 40 mg. The biological activities of the synthesised compounds
have been compared with standard drugs. The details have been cited in Part - I,
Section - I (E).
N
N
N SH
NH2
+ R-CHO
, 2-5 min
P-TSOH, DMF
N
N
N
S
NH
R
Type ( VIII )            R = Aryl
mg
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Type Vibration                Frequency in cm-1 Ref.
mode Observed Reported
30.0
35.0
40.0
45.0
50.0
55.0
60.0
65.0
70.0
75.0
80.0
85.0
90.0
95.0
100.0
105.0
% T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cm
Alkane C-H str. (asym.) 2923 2975-2950 351
-CH3 C-H str. (sym.) 2837 2880-2860 ,,
C-H def. (asym.) 1467 1470-1435 ,,
C-H def. (sym.) 1394 1395-1370 ,,
Aromatic C-H str. 3049 3080-3030 ,,
C=C str. 1492 1585-1480 ,,
C-H i.p. def. 1114 1125-1090 352
1026 1070-1000 ,,
C-H o.o.p. def. 833 835-810 ,,
Triazole C=N str. 1602 1612-1593 353
C-N str. 1172 1360-1310 ,,
N-N str. 1026* 1050-1010 ,,
Thiadiazole N-H str. 3419 3450-3200 354
N-H def. 1575 1650-1580 ,,
N-N str. 1026 1050-1010 ,,
C-S str. 684 720-570 ,,
* = overlap
N
N
N
S
NH
OCH 3
IR SPECTRAL STUDY OF 2-(ρ-ANISYL)-4-(1'-NAPHTHYL METHYL)-2,3-
DIHYDRO-1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Freq. range 4000-400 cm-1 (KBr disc.)
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N
N
N
S
NH
H3CO
OCH3
a
b
cd
e
f
g
h
i
j
k
Internal reference : TMS
Solvent : CDCl3 + DMSO-d6
Instrument : BRUKER Spectrometer (300 MHz)
Interpretation of Spectrum :
Signal Signal Position Relative No. Multiplicity Inference
No. (d ppm) of proton
1 3.81 3H singlet Ar–OCH3
2 4.93 3H singlet Ar–OCH3
3 4.60 2H singlet –CH2–
4 6.88 1H Doublet Ar–H (b)
5 7.26 1H Double Doublet Ar–H (e)
6 7.31 - 7.34 2H Multiplate Ar–H (a,f)
7 7.39 1H Triplet Ar–H (i)
8 7.44 - 7.53 2H Multiplate Ar–H (g,j)
9 7.74 1H Doublet Ar–H (c)
10 7.83 1H Multiplate Ar–H (h)
11 8.11 1H Double Doublet Ar–H (d)
12 9.96 1H Singlet –CH (k)
N
N
N
S
NH
H3CO
OCH3
a
b
cd
e
f
g
h
i
j
k
IR SPECTRAL STUDY OF 2-(3,4-DIMETHOXYPHENYL)-4-(1'-NAPHTHYL
METHYL)-2,3-DIHYDRO-1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLE
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4
0
m/z = 374 . 5
N N
N S
NH O
CH3
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-ARYL-4-
(1'-NAPHTHYLMETHYL)-2,3-DIHYDRO-1,2,4-TRIAZOLO[3,4-b]-1,3,4-
THIADIAZOLES
(A) Preparation of 1'-Naphthyl acetohydrazide
See Part - I, Section - I(A).
(B) Preparation of Potassium 1'-naphthyl acetamido dithiocarbamate
See Part - I, Section - I (B).
(C) Preparation of 3-Mercapto-4-N-amino-5-(1'-naphthylmethyl)-
1,2,4-triazole
See Part - I, Section - I (C).
(D) Preparation of 2-(ρ-Anisyl)-4-(1'-naphthylmethyl)-2,3-dihydro-
1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole
A mixture of  3-mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-triazole
(2.56 g, 0.01 M), ρ-anisaldehyde (1.39g, 0.01 M) and  ρ-TSOH (50 mg) in
dry DMF (50 ml) was refluxed for 12 hr. The reaction mixture was poured onto
crushed ice, when a solid seperated out which was filtered, washed with water
and c rys ta l l i sed f r o m  m e t h a n o l .  Yi e l d  1 .5g ,  40% ,  m . p .  143o C .
(C21H18N4OS, Required :  C, 67.36; H, 4.85; N, 14.96; Found : C, 67.33;
H, 4.87;  N, 14.97%, TLC Acetone : Benzene (3 : 7), Rf  : 0.61).
Similarly, other aromatic aldehydes have been condensed. The physical
constant are recorded in Table No. 8.
(E) Biological evaluation of 2-Aryl-4-(1'-naphthylmethyl)-2,3-dihydro-
1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles
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(E) Biological evaluation of 2-Aryl-4-(1'-naphthylmethyl)-2,3-dihydro-
1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles
Antimicrobial testing was carried out as described in Part - I,
Section - I(E). The zone of inhition of test solution are recorded in Graphical
Chart No. 8. Antitubercular screening of the compounds of  type (VIII) was carried
out by TAACF, Southern Research Institute, U. S. A. as described in Part - II,
Section I (E) and the percentage of inhibition data of the compounds are recorded
in Table No. 8a.
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8a 2-Cl-C6H4- C20H15N4SCl 378.8 163 51 0.44 14.79 14.81
8b 3-Cl-C6H4- C20H15N4SCl 378.8 158 70 0.59 14.79 14.80
8c 4-Cl-C6H4- C20H15N4SCl 378.8 160 62 0.62 14.79 14.81
8d 2,4-(Cl)2-C6H3- C20H14N4SCl2 413.3 171 46 0.54 13.56 13.59
8e 3,4-(OCH3)2-C6H3- C22H20N4O2S 404.4 170 45 0.57 13.85 13.82
8f 2-OH-C6H4- C20H16N4OS 360.4 192 39 0.55 15.54 15.58
8g 4-OH-C6H4- C20H16N4OS 360.4 147 43 0.52 15.54 15.57
8h 3-OH, 4-OCH3-C6H3- C21H18N4O2S 390.4 145 45 0.60 14.35 14.31
8i 4-OCH3-C6H4- C21H18N4OS 374.4 143 40 0.61 14.96 14.97
8j 2-CH3-C6H4- C21H18N4S 358.4 212 57 0.49 15.63 15.60
8k -CH=CH-C6H5 C22H18N4S 370.4 111 42 0.54 15.12 15.10
8l 2-NO2-C6H4- C20H15N5O2S 389.4 151 30 0.48 17.98 17.95
8m 3-NO2-C6H4- C20H15N5O2S 389.4 121 48 0.57 17.98 17.96
* TLC Solvent System : Acetone : Benzene : (3 : 7)
Comp.
No.
1
TABLE NO. 8 : PHYSICAL CONSTANTS OF 2-ARYL-4- (1 ' -NAPHTHYLMETHYL)-2 ,3-DIHYDRO-
1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLES
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GRAPHICAL CHART NO. 8 :  2-ARYL-4-(1'-NAPHTHYLMETHYL)-2,3-DIHYDRO-1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLEs
1
4
5
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART - I
Section -I I : Antimicrobial activity of 2-Aryl-4-(1'-naphthylmethyl)-2,3-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-
thiadiazoles
8b (19) 8c (16) 8i (18) 8b (15) 8e (19)
8f (20) 8h (16) 8k (17) 8f (17) 8l (18)
8j (20) 8j (18)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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TAACF, Southern Research Institute
Primary Assay Summary Report
Dr. A. R. Parikh
Saurashtra University
Sample Corp Where,  R= Supplier Assay  MTb MIC %          Comment
   ID   ID Strain           Inhib
162281 PG-36 4-OCH
3
-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 0 MIC Rifampin = 0.25µg/ml
@98& inhibition
162282 PG-37 C
6
H
5
-CH=CH- Sau. Uni. Alamar H37Rv >6.25 28                "
162283 PG-38 4-OCH
3
-3-OH-
             C
6
H
3
- Sau. Uni. Alamar H37Rv >6.25 0                "
162284 PG-39 2-OH-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 0                "
162285 PG-40 2:4-(Cl)
2
-C
6
H
3
- Sau. Uni. Alamar H37Rv >6.25 10                "
162286 PG-41 4-Cl-C
6
H
4
- Sau. Uni. Alamar H37Rv >6.25 16                "
162287 PG-42 3:4-(OCH
3
)
2
-
              C
6
H
3
- Sau. Uni. Alamar H37Rv >6.25 0                "
NIAID / Southern Research Institute / GWL Hansen's center / Colorado State University Proprietary Information
N
N
N
S
NH
R
TABLE NO. 8a : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
CONCLUSION
Looking to the activity table, it can be concluded that no compound is
significantly active.
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PART - II
STUDIES ON
N-THIOUREDO-
1,2,4-THIADIAZOLES
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INTRODUCTION
Thiosemicarbazides, also known as amino derivatives of thiourea, have
a skeleton of (I). Incorporation of thiosemicarbezide substituent in various
compounds enhance their biological activity. These compounds have found their
way into almost every branch of chemistry, commercially they are used as dyes,
photographic films, plastic and in textile industry.
Thiosemicarbazide and its derivatives are extensively used in medicine
especially in the treatment of tuberculosis300 and also used as insecticides,
preservatives, rodenticides and pharmaceuticals.
SYNTHETIC ASPECT
There are various methods for obtaining thiosemicarbazides. Different
methods for the synthesis have been cited in literature301-306.
1. V. N. Sonar and N. G. Purohit307 have synthesised thisemicarbazides
bearing indole nucleus.
( I )
R NH NH NH R1
S
R, R1 = Aryl / Alkyl
N
H
Ph
NH2
R
N
H
Ph
NH
R NH
NH2
S
(i) CS2, NaOH
(ii) NH2-NH2 H2O
( II )
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2. Perumal Yogeeswari et al.308 have been reported 6-chlorobenzotiazolyl-
2-thiosemicarbazones(III) as anticonvalsant and neurotoxic agent.
BIOLOGICAL SIGNIFICANCE
Thiosemicarbazides exhibit a wide variety of biological activities which
are listed as under :
1. Hypoglycemic309
2. Herbicidal310,311
3. Antileukemic312
4. Antiinflammatory313
5. Anticonvulsant314
6. Antitumor315,316
7. Antitubercular317,318
8. Anticancer319,320
9. Antimicrobial321
10. Antiviral322
Missbach Martin323 synthesised some new thisemicarbazides (IV) and
reported their use as antirheumatics. Sarkis324 and co-workers have prepared
N
SCl
NH2
N
SCl
NH NH NH2
S
N
SCl
NH NH N
S
R R1
(i) CS2 / THF
(ii) NH2-NH2 H2O
Ald. / KetoneGl. AcOH, EtOH
CRR1 = 3-isatinyl, 2-Cl-Ph, 2-OH-Ph, 5-Cl-3-isatinyl,
4-OH-acetophenone, 4-NO2-Acetophenone
( III )
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some new 2-quiniline carboxaldehyde thisemicarbazonesand their transition metal
complexes possessing antileishmanil activity. Z. Z. -Yi325, R. Sevim326 and A.
Gursoy327 have prepared thiosemicarbazides and reported their antimicrobial
activity. O.V. Fedorova et al.328 synthesised some new thiosemicarbazones (V)
having potent in vitro tuberculostatic activity.
M. Amir and S. Shahani329,330 have investigated some thiosemicarbazide
derivatives and reported antiinflammatory activity. R. Sevim et al.331 have
synthes i sed f luor ina ted th iosemicarbaz ide  der iva t ives  possess ing
antimycobacterial and anticonvulsant activity. Srivastava et al.332 have evaluated
thiosemicarbazide derivatives for antimicrobial and antiinflammatory activity.
Yogesh et al.333 have investigated fluorine substituted thiosemicarbazide
derivatives (VI) in search of antifungal and antitubercular activity. M. Srivastava
et al.334 have suggested quinazolinones containing thiosemicarbazide derivatives
(VII) and reported their antibacterial and antiviral activity.
F3C
NH
NH
NH
S
R
R R
R
NH
NH
S
N
N
O
CF3
R = 2'-F, 3'-F, CF3, 3'-Cl, 4'-Cl, 4'-F R = Aryl
( VII )( VI )
( IV )
S
N
H
S N NH NH R
S
NNHNH2
S
O
N NH2NH
S
( V )
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Leung Carmen et al.335prepared thiourea derivatives which is widely used
as bradkinin receptor antagonists. Rajanarendar E and co-workers336 have
suggested thiourea derivatives as bactericidal and fungicidal agents.Crisan O. et
al.337 reported thiosemicabazides bearing 1,2,4-triazole moiety(VIII) which is
having good anti-inflammatory activity and low toxicity.
Looking to the interesting property of thiosemicarbazides, it is thought worth
whileto synthesise thiosemicarbazides having triazole nucleus, we have
undertaken the preparation of thisemicarbazides which have been described in
current section.
N
N
N S
CH3
Ph
NH NH
NH2
S
O
( VIII )
SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-
4-N-ARYLTHIOUREDO-5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
Thiourea derivatives represent one of the most active classes of compounds
possessing wide spectrum of pharmacological potency. This has prompted us to
synthesise thiourea derivative of type (IX) by condensation of aryl isothiocyanates
(ITC) with 3-mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-triazole in DMF
as shown in reaction Scheme (IX).
The constitution of the products has been established by using elemental
analyses, infrared spectroscopy and 1H nuclear magnetic resonance spectroscopy
and further confirmed by mass spectrometry86. In mass spectroscopy
when R=p-anisyl m/z = 422 indicates the moleculer weight of the compound.
All the newly synthesised compounds have been screened for their in vitro
biological assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H37Rv at a concentration of 6.25 mg/ml using Rifampin as
standard drug, antibacterial activity towards Gram positive and Gram negative
bacterial strains and antifungal activity towards Aspergillus niger at a
concentration of 40 mg. The biological activities of the synthesised compounds
have been compared with standard drugs. The details have been cited in Part - I,
Section - I (E).
N
N
N
SH
NH2
Type ( IX )            R = Aryl
R-N=C=S
DMF,  stirring
N
N
N SH
NH
S
NH
R
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Type Vibration                Frequency in cm-1 Ref.
mode Observed Reported
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
% T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cm
Alkane C-H str. (asym.) 2950 2975-2950 351
-CH3 C-H str. (sym.) 2781 2880-2860 ,,
C-H def. (asym.) 1423 1470-1435 ,,
C-H def. (sym.) 1328 1395-1370 ,,
Aromatic C-H str. 3043 3080-3030 ,,
C=C str. 1566 1585-1480 ,,
1496 1520-1480
C-H i.p. def. 1164 1125-1090 352
1020 1070-1000 ,,
C-H o.o.p. def. 790 835-810 ,,
Triazole C-S-H str. 2358 2500-2400 353
C=N str. 1598 1612-1593 ,,
C-N str. 1423 1420-1020 ,,
N-N str. 1020 1050-1010 ,,
Thiourea N-H str. 3315 3450-3200 354
C-S str. 700 750-700 ,,
1251 1250-1200 ,,
N N
N
S
H
N
H
S
N
H
C
H
3
IR SPECTRAL STUDY OF 3-MERCAPTO-4-N-(ρ-TOLYL)-THIOUREDO-5-
(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Freq. range 4000-400 cm-1 (KBr disc.)
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N
N
N
SH
NH
NH CH3
S
h
h'
i
i'
cb
a
d
e f
g 1
2
N N
N
SH
NH
S
NH CH3
PMR SPECTRAL STUDY OF 3-MERCAPTO-4-N-(r-TOLYL)-THIOUREDO-5-
(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLE
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1
5
6
m/z = 421. 5 (m + 1)
N N
N
SH
NH
S
NH
O
CH3
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-
4-N-ARYLTHIOUREDO-5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
(A) Preparation of 1'-Naphthyl acetohydrazide
See Part - I, Section - I(A).
(B) Preparation of Potassium 1'-naphthyl acetamido dithiocarbamate
See Part - I, Section - I (B).
(C) Preparation of 3-Mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-
triazole
See Part - I, Section - I (C).
(D) Preparation of 3-Mercapto-4-N-(ρ-tolyl)-thiouredo-5-(1'-naphthyl
methyl)-1,2,4-triazole
A mixture of  3-mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-triazole
(2.56 g, 0.01 M) and 4-methylphenyl isothiocyanate (1.49 g, 0.01 M) in DMF
(40 ml) was added and the resulting solution stirred for half an hour at room
temperature.  The reaction mixture was poured onto crushed ice. The precipitated
solid which was f i l tered washed with water and crystal l ised from methanol.
Yield 2.4g, 59%, m.p. 198oC. ( C21H19N5S2, Required :  C, 62.19; H, 4.72; N,
17.27; Found : C, 62.22; H, 4.69; N, 17.24%, TLC Acetone : Benzene
(5 : 5), Rf : 0.61).
Similarly, other arylisothiocyanates were condensed. The physical constant
are recorded in Table No. 9.
(E) Biological  evaluation of  3-Mercapto-4-N-arylthiouredo-5-
(1'-naphthylmethyl)-1,2,4-triazoles
Antimicrobial testing was carried out as described in Part - (I),
Section - I(E). The zone of inhition of test solution are recorded in Graphical
Chart No. 9.
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9a 4-CH3-C6H4- C21H19N5S2 405.5 192 52 0.61 17.27 17.30
9b 4-OCH3-C6H4- C21H19N5OS2 421.5 216 58 0.48 16.61 16.62
9c 4-Cl-C6H4- C20H16N5S2Cl 425.9 208 45 0.55 16.44 17.45
9d 3-Cl-C6H4- C20H16N5S2Cl 425.9 156 48 0.63 16.44 16.41
9e 2-OCH3-C6H4- C21H19N5OS2 421.5 242 55 0.56 16.61 16.64
9f 2-CH3-C6H4- C21H19N5S2 405.5 275 46 0.47 17.27 17.29
9g 4-NO2-C6H4- C20H16N6O2S2 436.5 260 49 0.53 19.25 19.29
9h 2-NO2-C6H4- C20H16N6O2S2 436.5 275(d) 57 0.54 19.25 19.27
9i C6H5- C20H17N5S2 391.5 194 46 0.67 17.89 17.91
9j 2-Cl-C6H4- C20H16N5S2Cl 425.9 255 59 0.63 16.44 16.47
* TLC Solvent System :  Acetone : Benzene : (5 : 5)
Comp.
No.
1
TABLE NO. 9 : PHYSICAL CONSTANTS OF 3-MERCAPTO-4-N-ARYLTHIOUREDO-5-(1 ' -NAPHTHYL
METHYL)-1,2,4-TRIAZOLES
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GRAPHICAL CHART NO. 9 : 3-MERCAPTO-4-N-ARYLTHIOUREDO-5-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLES
1
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0
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART - II
Section - I : Antimicrobial activity of 3-Mercapto-4-N-arylthiouredo-5-(1'-naphthylmethyl)-1,2,4-triazoles
9b (18) 9f (21) 9d (18) 9a (16) 9a (20)
9f (19) 9h (16) 9h (17) 9e (19)
9j (20) 9i (15) 9h (21)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 2-ARYLAMINO-
4-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLES
Amino thiadiazole have been found to be associated with broad spectrum
of biological activities. In view of these valid observations, it was contemplated
to synthesise some new thiadiazoles of type (X) possessig higher therapeutic
activity bearing 1,2,4 triazole nucleus. To achieve better potency, different type
of thiadiazoles (X) have been carried out by the action of thiourea derivatives of
type (IX) in DMF, as shown in reaction scheme (X).
The constitution of the products has been established by using elemental
analyses, infrared spectroscopy and 1H nuclear magnetic resonance spectroscopy
and further confirmed by mass spectrometry86. In mass spectroscopy
when R=p-anisyl m/z = 388 indicates the moleculer weight of the compound.
All the newly synthesised compounds have been screened for their in vitro
biological assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H37Rv at a concentration of 6.25 mg/ml using Rifampin as
standard drug, antibacterial activity towards Gram positive and Gram negative
bacterial strains and antifungal activity towards Aspergillus niger at a
concentration of 40 mg. The biological activities of the synthesised compounds
have been compared with standard drugs. The details have been cited in Part - I,
Section - I (E).
Type ( X )            R = Aryl
-H2S
DMF,  Reflux
N
N
N
S
N
NH R
N
N
N SH
NH
S
NH
R
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Type Vibration                Frequency in cm-1 Ref.
mode Observed Reported
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
% T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cm
Alkane C-H str. (asym.) 2921 2975-2950 351
-CH3 C-H str. (sym.) 2850 2880-2860 ,,
C-H def. (asym.) 1467 1470-1435 ,,
C-H def. (sym.) 1396 1395-1370 ,,
Aromatic C-H str. 3049 3080-3030 ,,
C=C str. 1569 1585-1480 ,,
1467* 1520-1480 ,,
C-H i.p. def. 1112 1125-1090 352
1026 1070-1000 ,,
C-H o.o.p. def. 829 835-810 ,,
Triazole S-C=N str. 1602 1640-1605 353
N-N str. 993 1050-1000 ,,
C-N str. 1172 1220-1020 ,,
C-S-C str. 603 700-600 ,,
Amino N-H str. 3413 3450-3200 351
N-H def. 1602* 1650-1580 ,,
* = overlap
N
N
N
S
N
NH CH3
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Freq. range 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 2-(ρ-TOLYLAMINO)-4-(1'-NAPHTHYLMETHYL)-
1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLE
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PMR SPECTRAL STUDY OF 2-(r-TOLYLAMINO)-4-(1'-NAPHTHYLMETHYL)-
1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLE
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1
6
6
m/z = 387. 5
N N
N S
N
NH
O
CH3
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-ARYLAMINO-
4 - ( 1 ' - N A P H T H Y L M E T H Y L ) - 1 , 2 , 4 -T R I A Z O LO [ 3 , 4 - b ] - 1 , 3 , 4 -
THIADIAZOLES
(A) Preparation of 1'-Naphthyl acetohydrazide
See Part - I, Section - I(A).
(B) Preparation of Potassium 1'-naphthyl acetamido dithiocarbamate
See Part - I, Section - I (B).
(C) Preparation of 3-Mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-
triazole
See Part - I, Section - I (C).
(D) Preparation of 3-Mercapto-4-N-(r-tolyl)-thiouredo-5-(1'-naphthyl
methyl)-1,2,4-triazole
See Part - B-II, Section - I (D).
(E) Preparation of  2-(ρ-Tolyl)-amino-4-(1'-naphthylmethyl)-1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazole
A solution of 3-Mercapto-4-N-(ρ-tolyl)-thiouredo-5-(1'-naphthylmethyl)-
1,2,4-triazole (4.06g, 0.01 M) in DMF (40 ml) was heated under reflux for 8 hrs.
The contents were poured onto crushed ice. The product was isolated crystallised
from methanol. Yield 2.2g, 60%, m.p. 205oC. ( C21H17N5S, Recquired
: C, 67.90; H, 4.61; N, 18.85; Found : C, 67.92; H, 4.64; N, 18.81%,
TLC Acetone : Benzene (4 : 6), Rf : 0.51).
Similarly, other coumpounds have been prepared. The physical constant
are recorded in Table No. 10.
(F) Biological evaluation of 2-Arylamino-4-(1'-naphthylmethyl)-1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazoles
Antimicrobial testing was carried out as described in Part - I, Section - I(E).
The zone of inhition of test solution are recorded in Graphical Chart No. 10.
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TABLE NO. 10 : PHYSICAL CONSTANTS OF 2-ARYLAMINO-4-(1'-NAPHTHYLMETHYL)-1,2,4-TRIAZOLO
[3,4-b]-1,3,4-THIADIAZOLES
10a 4-CH3-C6H4- C21H17N5S 371.4 185 48 0.51 18.85 18.88
10b 4-OCH3-C6H4- C21H17N5OS 387.4 275 53 0.56 18.08 18.11
10c 4-Cl-C6H4- C20H14N5SCl 391.8 180 49 0.61 17.87 17.83
10d 3-Cl-C6H4- C20H14N5SCl 391.8 245 42 0.46 17.87 17.84
10e 2-OCH3-C6H4- C21H17N5OS 387.4 260 59 0.57 18.08 18.12
10f 2-CH3-C6H4- C21H17N5S 371.4 214 62 0.67 18.85 18.88
10g 4-NO2-C6H4- C20H14N6O2S 402.4 272 64 0.61 20.88 20.91
10h 2-NO2-C6H4- C20H14N6O2S 402.4 196 51 0.54 20.88 20.88
10i C6H5- C20H15N5S 357.4 170 48 0.58 19.59 19.61
10j 2-Cl-C6H4- C20H14N5SCl 391.8 208 65 0.63 17.87 17.83
* TLC Solvent System : Acetone : Benzene : (4 : 6)
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COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART - II
Section - II : Antimicrobial activity of 2-Arylamino-4-(1'-naphthylmethyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles
10g (20) 10b (16) 10j (18) 10a (16) 10g (20)
10j (21) 10c (17) 10c (15) 10j (21)
10h (16) 10f (17)
10j (16)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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   PART - III
MICROWAVE ENHANCED
SYNTHESIS OF
1,3,4-THIADIAZOLES
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INTRODUCTION
Microwave radiation is a descriptive term used to identify electromagnetic
waves in frequency spectrum ranging from 1 Giga Hertz (10 Hz) to 30 Giga Hertz.
These waves present several interesting and unusual features not found in other
portions of the electromagnetic spectrum. These features make "microwaves"
uniquely suitable for several useful applications like industrial, scientific, domestic
and medicinal.
The rapid heating of foodstuffs in microwave oven is routinely used by a
significant proportion of mankind. However people have recognised other
potential applications for this method of heating and scientists engaged in a
number of disciplines have applied the rapid heating associated with microwave
technology to a number of useful processes. These include the preparation of
samples for analysis338, appl icat ions to waste treatment339, polymer
technology340, drug release/targeting341 and ceramics342. The technique has
also found use in a range of decomposition processes including hydrolysis of
proteins and peptides.
Microwave heating is distinguished primarily by being a radiant process.
Its relationship to ordinary heat is of much interest. Regular heat rays differ in
frequency and properties. In the conventional method, heat is generated by
molecular collisions which accomplish the energy transfer while microwaves cause
heating through the absorption of energy quanta. Microwave generate
instantaneous "incore" heating of materials, in a homogeneous and selective
manner, especially those with poor heat conduction properties.
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When molecules with permanent dipole are submitted to an electric field,
they become aligned. If this field oscillates, the orientation changes at each
alternation. The strong agitation, provided by the reorientation of molecules, in
phase with the electrical field excitation, causes an intense internal heating, upto
10oC per second, when powerful waves are used.
The main interests can thus be listed as the rapid transfer of energy into
the bulk of the reaction mixture, without inertia since only the product is heated
and the ease of utilisation. Furthermore, as the depth of penetration in materials
is of the same order of magnitude as the wavelength, microwaves interact with
substances of appreciable thickness (about 10 cm).
The interfacial polarisation, the Maxwell-Wagner effect, may also contribute
to the heating effect when the conducting particles are in contact with a non
conducting medium, e.g. in heterogenous reactions. It is particularly convenient
that qualitatively, the larger the dielectric constant, the greater the coupling with
microwaves. Thus solvents such as water, methanol, DMF, ethyl acetate,
chloroform, acetone, acetic acid and dichloromethane are all heated when
irradiated with microwaves. Non-polar solvents do not couple and therefore do
not heat with microwave irradiation.
Since solvents were used in these experiments, some problems with
safe operation appeared and sometimes explosion resulted. Further development
demonstrated the potential of solvent free reaction to solve these problems and
to facilitate the scale-up of preparative runs. Recently, reactions under dry
conditions using inorganic reagents are gaining more attention because of their
enhance selectivity and milder conditions than those associated with conventional
homogeneous reaction procedures. It should be noted that some of inorganic
additives reach temperatures in excess of 1000oC very rapidly and decomposition
of materials may be problematic, therefore the some precautions regarding
superheating and associated fire hazards or explosions are taken.
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APPLICATION IN ORGANIC SYNTHESIS
The first applications of microwave ovens in organic synthesis began very
recently. In the first experiments, Gedye, and then Giguere, provided evidence
for dramatic accelerations in some classical organic reactions, and these were
ascribed to temperature and pressure effects, when performed in closed Teflon
vessels. Since solvents were used in these experiments, some problems with safe
operation appeared, and explosions sometimes resulted. Further developments
demonstrated the potential of solvent-free reactions to solve these problems and
to facilitate the scale-up of preparative runs.
Three types of solvent-free procedures can be coupled with microwave
activation.
i) Reactions between neat reactants, needing at least one polar molecule, as
liquid-liquid or liquid-solid systems. In this latter case, reactions presumably occur
at the interface due to adsorption of the liquid reactant at the surface of the solid
one.
ii) Reactions between suppoted reagents on solid mineral supports in <<
dry media>> by impregnation of compounds on alumina, silicas or clays.
iii) Phase Transfer Catalysis (PTC) conditions in the absence of organic solvent,
i.e. when a liquid reagent acts both as a reactant and an organic phase. This last
methodology can also be improved under sonochemical activation.
Microwave constitutes very original procedure for heating materials, clearly
different from the classical ways. Their main advantages derive from the almost
instantaneous "in core" heating of materials, in an homogeneous and selective
manner, especially those with poor heat conduction properties. This technique
proves to be excellent in cases where traditional heating has a low efficiency
because of poor heat transmission, and hence local overheating is a major
inconvenience.
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The main interests can thus be listed as the rapid transfer of energy into
the bulk of the reaction mixture, without inertia since only the product is heated,
and the ease of utilization. Furthermore, as the depth of penetration in materials
is of the same order of magnitude as the wavelength, microwaves interact with
substances of appreciable thickness (about 10 cm).
The use of domestic microwave oven in this regard is now a well established
procedure in MORE (Microwave Inclided Organic Reaction Enhancement). It has
been reported that the rate of variety of organic reaction such as
1. Diels-Alder
2. Claisen reaction
3. Oxidation
4. Reduction
5. Diacetylation
6. Deacetylationm
7. Esterification
8. Hydrolysis of esters
9. Doener condensation
10. Knoevenagel condensation
could be enhanced by microwave irradiation.
SYNTHETIC ASPECT
Microwave assisted chemical reactions are gaining importance due to
advantages and environmentally friendly process they offer, as compared to
conventional reactions. Various methods for synthesis of triazolo-thiadiazol
derivatives using microwave heating is reported in literature343-350. These
compounds have been synthesised using conventional heating which is reported
in Part-I Section - II.
SECTION-1 : MICROWAVE INDUCED AN EXPEDITIOUS SYNTHESIS
OF 2-ARYL-4-(1'-NAPHTHYLMETHYL)-2,3-DIHYDRO-
1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLES
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N
N
N SH
NH2
+ R-CHO
, 2-5 min
P-TSOH, DMF
N
N
N
S
NH
R
Type ( VIII )            R = Aryl
SECTION - I
MICROWAVE INDUCED AN EXPEDITIOUS SYNTHESIS OF 2-ARYL-
4-(1'-NAPHTHYLMETHYL)-2,3-DIHYDRO-1,2,4-TRIAZOLO[3,4-b]-
1,3,4-THIADIAZOLES
As a part of our research programme directed towards the non-traditional
approach to the experimental setup of organic reactions, the concept of
"Microwave Induced Organic Reaction Enhancement" (MORE) chemistry has been
utilised for rapid and efficient synthesis of some 2-aryl-4-(1'-naphthylmethyl)-
2,3-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles by the condensation
of 3-mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-triazole with different
aromatic aldehydes in presence of r-toluene sulphonic acid under microwave
irradiation. The reaction scheme is shown as under.
The constitution of the synthesized products has been established using
elemental analysis, infrared spectroscopy and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
It can be concluded from Table No. 11 that by using classical method, the
condensation of triazole with aldehyde required 12 hrs. time, while same reaction
using microwave irradiation required only 3 minutes and led to the imporvement
in yield, representing a dramatic 240 fold decrease in reaction time.
mg
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EXPERIMENTAL
MICROWAVE INDUCED AN EXPEDITIOUS SYNTHESIS OF 2-ARYL-
4-(1'-NAPHTHYLMETHYL)-2,3-DIHYDRO-1,2,4-TRIAZOLO[3,4-b]-
1,3,4-THIADIAZOLES
A mixture of 3-mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-
triazole(2.56 g, 0.01 mol), ρ-Anisaldehyde (1.36 g, 0.01 mol) and
ρ-toluenesulphonic acid (5 mg) in DMF (20 ml) taken in a round bottom flask
fitted with a ice cold reflux condensor, was irradiated in a microwave oven for
2.5 min (at 270 Watts i.e. 30% microwave power). None of the reaction were
irradiated longer than 2 min at a time to completion of the reaction (TLC), the
reaction mixture was cooled and poured onto crushed ice, filtered and crystallised
from ethanol.
Similarly, other triazolo-thiadiazoles were prepared by irradiating
3-mercapto-4-N-amino-5-(1'-naphthylmethyl)-1,2,4-triazole with different
aromatic aldehydes.
A comparable study in terms of yield and reaction period is recorded in
Table No. 11.
Higher temperature conditions were found in the case where DMF has been
added. This indicates that DMF acts as energy transfer medium and is responsible
for the enhancement of yields.
The essential microwave oven manufactured by LG Electronics Limited
(India) has been used. It has a range of microwave output of 900 watts.
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TABLE NO. 11  :   COMPARISON OF CONVENTIONAL METHOD AND
MICROWAVE ENHANCED SYNTHESIS OF 2-ARYL-
4-(1'-NAPHTHYLMETHYL)-2,3-DIHYDRO-1,2,4-
TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLES
Compd.
No. R
Thermal
Reaction period   Yield
      (hrs.)           (%)
Microwave
Reaction Period   Yield
      (min.)            (%)
   MP
  (oC)
11a CH=CH-C6H5- 14 42 3.0 50 111
11b 3-OH, 4-OCH3-C6H3- 15 45 3.5 68 145
11c 4-OH-C6H4- 12 43 2.5 65 147
11d 2-Cl-C6H4- 12 51 3.5 76 163
11e 2,4-(Cl)2-C6H3- 15 46 4.0 62 171
11f 2-OH-C6H4- 16 39 2.0 78 192
11g 2-CH3-C6H4- 13 57 3.0 75 212
11h 4-OCH3-C6H4- 14 40 3.5 68 143
11i 2-NO2-C6H4- 15 30 4.5 60 151
11j 3:4 (OCH3)2-C6H3- 18 45 3.0 72 170
11k 3-Cl-C6H4- 12 70 3.5 70 158
11l 4-Cl-C6H4- 13 62 3.5 75 160
11m 3-NO2-C6H4- 14 48 5.0 65 121
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2-Cl-C6H4-
3-Cl-C6H4-
4-Cl-C6H4-
2:4-(Cl)2-C6H3-
3:4 (OCH3)2-C6H3-
2-OH-C6H4-
4-OH-C6H4-
4-OCH3,3-OH-C6H3-
4-OCH3-C6H4-
C6H5-CH=CH-
2-NO2-C6H4-
3-NO2-C6H4-
N
N
N
SH
N
R
N
N
N
SH
NH
R
O
C6H5-
2-NH2-C6H4-
3-NH2-C6H4-
3-C5H4N-
4-Br-C6H4-
4-Cl-C6H4-
3,4-(NO2)2-C6H3-
4-OCH3-C6H4-
2-CH3-C6H4-
3-CH3-C6H4-
4-CH3-C6H4-
C6H5-CH=CH-
R R
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N N
N S
N N
CH3
R
N
N
N N
N S
N
R
O
C6H5-
2-NH2-C6H4-
3-NH2-C6H4-
3-C5H4N-
4-Br-C6H4-
4-Cl-C6H4-
3,4-(NO2)2-C6H3-
4-OCH3-C6H4-
2-CH3-C6H4-
3-CH3-C6H4-
4-CH3-C6H4-
C6H5-CH=CH-
H
6-Cl
7-Cl
8-Cl
6-Cl, 5-F
6:7-(Cl)2
6:8-(CH3)2
7:8-(CH3)2
6-OCH3
6-CH3
7-CH3
8-CH3
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N N
N SH
R
N
N
N SH
NH
SO2
R
4-CH3-C6H4-
4-Br-C6H4-
4-NHCOCH3-C6H4-
4-Cl,3-COOH -C6H3-
4-Cl-C6H4-
3-CH=CH-C6H5-
3-COOH -C6H5-
2,4-(Cl)2-C6H3-
4-F-C6H4-
3-COOH, 4-OH, -C6H3-
3-COOH, 4-OCH3 -C6H3-
3-COOH, 4-NO2 -C6H3-
C6H5-
2-Cl-C6H4-
3-Cl-C6H4-
4-Cl-C6H4-
3,4-(Cl)2-C6H3-
2,3-(CH3)2-C6H3-
2,4-(CH3)2-C6H3-
3-OCH3-C6H4-
4-OCH3-C6H4-
2-CH3-C6H4-
3-CH3-C6H4-
4-CH3-C6H4-
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N
N
N
S
NH
R
N
N
N
S
N
R
3-C5H4N-
2-NH2-C6H4-
3-NH2-C6H4-
4-NH2-C6H4-
4-Br-C6H4-
4-Cl-C6H4-
2,4-(OH)2-C6H3-
3,4-(NO2)2-C6H3-
2-OH-C6H4-
4-OCH3-C6H4-
3-CH3-C6H4-
-CH=CH-C6H5
2-Cl-C6H4-
3-Cl-C6H4-
4-Cl-C6H4-
2,4-(Cl)2-C6H3-
3,4-(OCH3)2-C6H3-
2-OH-C6H4-
4-OH-C6H4-
3-OH, 4-OCH3-C6H3-
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N
N
N
S
N
NH R
N
N
N SH
NH
S
NH
R
4-CH3-C6H4-
4-OCH3-C6H4-
4-Cl-C6H4-
3-Cl-C6H4-
2-OCH3-C6H4-
2-CH3-C6H4-
4-NO2-C6H4-
2-NO2-C6H4-
C6H5-
2-Cl-C6H4-
4-CH3-C6H4-
4-OCH3-C6H4-
4-Cl-C6H4-
3-Cl-C6H4-
2-OCH3-C6H4-
2-CH3-C6H4-
4-NO2-C6H4-
2-NO2-C6H4-
C6H5-
2-Cl-C6H4-
